Key findings

  • 17.3% vs 21.9%mortality risk with high dose online haemodiafiltration versus conventional haemodialysis over 30 months in the CONVINCE trial (p < 0.005)
  • 31% and 22%reduction in cardiovascular and all-cause mortality associated with a convective volume of 55-75 L/week in earlier haemodiafiltration trials
  • 21%reduction in the risk of death over 4 years with the medium cut-off dialyzer (559 patients) compared with high-flux haemodialysis (533 patients)
  • 2-4 galbumin lost per session with the medium cut-off dialyzer, an insignificant loss according to the studies of Storr and Ward

Abstract

Chronic kidney disease is a progressive loss of renal function that may lead to kidney failure. Kidney transplantation is the gold standard of kidney replacement therapy. Haemodialysis and peritoneal dialysis remain the alternative replacement therapies, where haemodialysis is the predominant dialysis modality globally. Haemodialysis is a supportive therapy that purifies blood from accumulated uremic toxins, removing excess fluids, and maintaining electrolytes and acid-base balance. It’s usually conducted over 4 hours three times per week in a hospital-based unit, but it can also be performed in satellite units or at home. There are three combined physiological mechanisms in performing haemodialysis therapy. These are diffusion, ultrafiltration, and convection. Performing haemodialysis requires haemodialysis machine, dialyzer (membrane or filter), fistula needles, blood lines, buffers and electrolytes, vascular access, and treated water. Conventional haemodialysis is performed by using low-flux or high-flux dialyzers. This modality of dialysis is quite efficient in clearing soluble small-size uremic toxins, such as urea and creatinine. Although conventional haemodialysis is supportive therapy for patients with kidney failure, it has limited capacity in clearing large-size molecules, due to inefficient implementation of the physiological principle of convection. These molecules include alpha 1-microglobulin, fibroblast growth factor-23, YKL-40, and kappa and lambda free light chains. Retention of these molecules not only associated with poor quality of life, but are also associated with inflammation, atherosclerosis and vascular calcifications, all of which can increase the risk of cardiovascular disease and death. Recent haemodialysis modalities are empowered with effective convection to remove these molecules. These advanced modalities include online haemodiafiltration and expanded haemodialysis, both of which are safe, efficient, and have been associated with increased survival rate and improved quality of life. This article reviews the basic physiological principles of conventional haemodialysis, its components, prescription, dialysis adequacy, anticoagulation, anticoagulation sparing strategies, and medications prescription. It also reviews the advanced haemodialysis modalities and compares their implementation and clinical outcomes with conventional haemodialysis.

Introduction

Chronic kidney disease (CKD) is a progressive loss of renal function. It is defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines as decreased glomerular filtration rate (GFR) <60 ml/min/1.73 m2 and/or presence of one or more marker of kidney damage for more than 3 months. KDIGO also classified CKD into five stages/grades based on GFR, and albuminuria into 3 categories, all of which can assess and evaluate the prognosis of CKD.1 The most common causes of CKD are diabetes mellitus (diabetes) and hypertension, but other risk factors include glomerulonephritis, chronic pyelonephritis, polycystic kidney disease, renal obstructive causes (e.g., kidney stones and prostate enlargement), heart disease, obesity, and aging.2–4 CKD prevalence varies widely,5–7 but it does constitute a significant global health problem.8 Recent data showed that it affects more than 850 million people globally.9 Currently, CKD is the seventh leading risk factor for mortality worldwide, and it’s projected to become the fifth leading cause of death by 2040.4,10,11

In the absence of kidney transplantation, due to either shortage of live and deceased kidney doners or unsuitability of some patients, haemodialysis (HD) and peritoneal dialysis (PD) are the alternative kidney replacement therapy (KRT) options. HD is the predominant dialysis modality globally (88-89%), while PD accounts for only 11-12%.7 Both dialysis modalities achieve similar long-term survival rate, even in patients with diabetes.12 HD patients are usually treated in hospital-based dialysis unit or in a standalone HD unit (in-center HD) under the supervision of medical and nursing staff. HD can also be performed in satellite units or at home (home HD).

Haemodialysis is a supportive therapy for patients with kidney failure. It replaces the kidney function by purifying the blood from accumulated uremic toxins, removing excess fluids, and maintaining electrolytes and acid-base balance. HD therapy is usually conducted over 4 hours three times per week, but it has also been implemented as short daily dialysis (2 hours - 2 hours and 30 minutes)13 and nocturnal HD over 6-8 hours.14 These, and other, modalities are reviewed in.15 The performance of HD technique requires vascular access, HD machine (single or double pump), filter or dialyzer, fistula needles, bloodlines, bicarbonate and acid concentrate, and treated or purified water (water treatment station or plant).

Haemodialysis is expensive therapy, where about 2–4% of the healthcare budget typically spent on just 0.1–0.2% of the population.11 Healthcare providers in many countries are facing increasing challenges in managing patients with kidney failure. This is due, at least in part, to the progressive and significant increase in number of patients with CKD in need for KRT. The recent incidence of KRT patients from 19 Central and Eastern European countries between the years 2010 and 2021 showed increased rate from 106.3 per million population (pmp) in 2010 to 119.6 pmp in 2019. The overall KRT prevalence increased from 426.2 pmp in 2010 to 651.2 pmp in 2019, though trends differed within the region.16 The progressive increase in number of patients with kidney failure in need for KRT led to overwhelming financial burden with limited resources, especially in lower income countries.17–19

Conventional HD is performed by using low-flux or high-flux dialyzers, and the implementation of the physiological principle of diffusion, but to a much lower extent convection. Diffusion capability of purifying blood from uremic toxins is limited to the removal of soluble small size molecules less than 500 Daltons, such as urea and creatinine. Whereas removal of large-size molecules requires convection. The longterm outcomes in patients on conventional HD are still unsatisfactory. Patients are often inflammed, malnourished, and anaemic. Quality of life and rehabilitation are suboptimal. These include impaired physical function, poor post HD recovery time, pruritus, and restless leg syndrome. In addition, cardiovascular and all-cause mortality remain unacceptably high.15 These poor clinical outcomes have been associated with the retention of a wide spectrum of large-size molecules in the blood due to insufficient cleansing by conventional HD. These molecules include alpha 1-microglobulin, fibroblast growth factor-23, YKL-40, and kappa and lambda free light chains. High levels of such molecules correlate with inflammation, atherosclerosis and vascular calcifications, all of which increases the risk of cardiovascular and all-cause mortality. Retention of these molecules are also associated with poor quality of life. Their efficient clearance requires the implementation of the physiological principle of convection. Recent HD modalities are empowered with convection for effective removal of the larger molecules. These advanced modalities include online haemodiafiltration and expanded haemodialysis.

Following the description of basic physiological principles of HD, HD components and techniques, and its prescription and adequacy assessment, anticoagulation, and anticoagulation sparing strategies, this article provides an update on uremic toxins and the association of their retention with the clinical outcomes. It also reviews the advanced haemodialysis modalities and compares their implementation and clinical outcomes with conventional haemodialysis.

Physiological principles of haemodialysis

There are three combined physiological mechanisms in performing the HD therapy. These are diffusion, ultrafiltration, and convection.

Diffusion: The physiological principle of diffusion was established by the Scottish chemist Graham Thomas in 1856.20 Diffusion is defined by the movement of molecules across semipermeable membranes from high concentration (blood) to lower concentration (dialysate-cleansing fluid) until an equilibration is achieved between the two compartments (figure 1). Diffusion only allows the clearance of small soluble molecules with a molecular weight (MW) of less than 500 Daltons (Da), such as urea (60 Da) and creatinine (113 Da).

Figure 1. Diffusion: The movement of solutes from a higher to lower concentration compartment across a semipermeable membrane until an equilibration is achieved between the two compartments

Ultrafiltration: is defined as the ability of removing excess extracellular fluid across semipermeable membranes by applying hydrostatic or positive pressure to the blood compartment, and/or negative pressure on the dialysate compartment21 (figure 2).

Figure 2. Ultrafiltration: The movement of fluid through a semipermeable membrane caused by a pressure gradient. A positive pressure on the left compartment will “push” fluid through the membrane, and a negative pressure on the right compartment will “pull” fluid through the membrane.

Convection or solute drag, is the third physiological principle, where the ultrafiltered (blood) water carries the dissolved sluggish larger-size molecules (above 500 Da) across a semipermeable membrane into the other (dialysate) compartment22 (figure 3).

Figure 3. Convection: The movement of solutes with a fluid flow, solvent drag - the movement of membrane-permeable solutes with ultra filtrated water - during ultrafiltration.

The efficiency of clearing uremic toxins by these combined physiological principles is based on applying a counter-current flow mechanism in HD machines. This means blood and dialysate move in opposite directions to maintain the maximum concentration gradient along the entire length of the dialyzer and optimize the waste removal. The convective transport properties of a dialysis membrane for a specific solute are assessed by its sieving coefficient (SC). The SC is defined as the ratio of solute concentration in the filtrate over the solute concentration in plasma water in the absence of diffusion gradient across the membrane.23,24 The SC of 1.0, for example, indicates total clearance of a solute.

Components of haemodialysis technique

Haemodialysis machine

In recent decades, there has been significant improvements in the technology of HD machines. These include designs, multifunctional digital touch screens, options of different HD modalities, assessment of dialysis adequacy and ultrafiltration control.25–27 The components of HD machine include (a) extracorporeal or blood circuit (figure 4), where an installed pump controls the pressure of drawing the blood from the patient’s vascular access to the dialyzer/filter, pressure monitors to detect blockages or issues with the vascular access, and heparin pump for the continuous delivery of heparin to prevent extracorporeal blood clotting, (b) dialysate circuit, which is capable of preparing, mixing, and warming the delivered purified water with bicarbonate and acid concentrate to form the dialysate fluid under controlled temperature and required ultrafiltration. Dialysate fluid is necessary to remove filtered uremic toxins, excess fluids and maintain electrolytes and acid-base balance, and (c) safety monitors, which include air and blood leak detectors. The HD machine is equipped with holders for the dialyzer and bicarbonate cartridge, and a lower shelf for holding the acid concentrate.28 Advanced HD machines include additional pump (substitution fluid or infusion pump) for replacement fluids, as in specific HD modalities (e.g., haemodiafiltration), and filters for endotoxins removal to ensure purity of water.29

Figure 4. Haemodialysis extracorporeal circuit

Dialyzer

The dialyzer is the filter that’s made up of thousands of semipermeable hollow-fibers membranes (cannulated tubes), with variable sizes and distribution of pores, that allow blood to pass through and filter uremic toxins and remove excess fluids (figure 5). The hollow-fibers are usually synthetic and biocompatible membranes.30 They are composed of different polymers, including hydrophilic (allows for water-soluble diffusive solutes removal) and/or hydrophobic (allows for convective solute removal) membranes.31 Over the last few decades, there has been a significant improvement in dialyzers compatibility and membrane permeability. These improvements include adjustment of pore size, pore density and distribution, and length, thickness and inner diameters of the hollow-fibers.24,32 The safest method of sterilization of dialyzers is by steam, unlike the previous methods of using ethylene oxide or gamma radiation.24,33,34

Figure 5. A diagrammatic picture of a dialyzer.

Fistula needles

Haemodialysis fistula needles are designed with sharp tips for smooth insertion with flexible butterfly wings for secure taping and color-coded hubs for different gauges (variable diameters, where the smaller the gauge the larger the diameter) that stands high blood flow rates.35

Bloodlines

Haemodialysis bloodlines are sterile tubing, which connect patient’s vascular access to the HD machine. They are a set of arterial (red color that withdraws patient’s blood to the dialyzer, and venous tubing (blue color that returns the purified blood to patient).36

Buffers and electrolytes

Patients with kidney failure suffer from metabolic acidosis. Adding a buffer (bicarbonate with a preferred concentration 32 mEq/L) to the dialysis fluid, can help in correcting the metabolic acidosis. Currently, bicarbonate is supplied in cartridges, where it is mixed automatically with the supplied purified water. These cartridges replace the old system of mixing bicarbonate powder with water in tanks externally, which use to lead to contamination and precipitation of bicarbonate. Acid concentrate (e.g., acetate and more recently citrate) is added to avoid the binding of bicarbonate with some of the calcium and magnesium in water resulting in the precipitation of calcium carbonate and magnesium carbonate salts. Electrolytes are also added to the dialysis fluid in variable concentrations. The preferred concentration in mEq/L of sodium is 137, potassium 2-3, calcium 2.5, magnesium 1.0. Dextrose, as a source of energy, is also added in average concentration of 100 mg/dl.37

Vascular access

The vascular access is the lifeline for patients in need of HD. There are three types of vascular access: arterio-venous fistula (AVF), arterio-venous graft (AVG), and central venous catheters (CVC). Each of these has its uses and advantages and disadvantages. The AVF is created by connecting an artery and vein, usually in the forearm or upper arm. This technique, which takes 2 to 4 months to mature, increases collateral veins and their vasodilatation allowing for easier and repeated access to achieve high blood flow rate. AVF is the preferred method for safety and longevity.38 The AVG is a soft, synthetic tube used to connect an artery and vein in the upper arm, if natural vessels are too small. It’s associated with increased risk of clotting and infection, but can be used within 2-3 weeks after the tissue around the synthetic tube is healed and the swelling subsided.39 CVC is a temporary soft tube inserted into a large vein in the neck (internal jugular vein) or groin (femoral vein) that can be used instantly, where it’s often used for emergency HD. However, CVCs are usually associated with increased risk of infection and sepsis.40

Water treatment

The purity of water is vital and essential for HD treatment.41 Contaminated water with bacteria and endotoxins may lead to bacteremia and sepsis, and high levels of chemicals (e.g., aluminum, chloramine, copper, calcium, and zinc), may lead to haemodialysis, anaemia, bone disease, neurological deterioration, nausea and vomiting, hypotension and hypertension, metabolic acidosis, and death.42–44 Ultrapure water is defined by the ISO 23500 series (specifically ISO 23500-3 and ISO 23500-5) and the European Pharmacopoeia of less than 0.1 colony factor unit (CFU)/ml and endotoxin level less than 0.03 endotoxin unit (EU)/ml, including strict control of chemical purity.45 This definition is widely accepted and documented in international guidelines.46

The water treatment station or plant, which takes a large room space, is composed of multiple components41,44 (figure 6). These include (a) carbon tanks/carbon adsorption to remove chlorine/chloramine effectively, which are added to the city water supply to disinfect the potable water and reduce the risk of bacterial contamination, (b) sediment filters to remove large particulates of 10 microns or greater that cause the supply water to be turbid, (c) softeners which turn hard water into “soft” water by removing the hardness of excess calcium and magnesium, (d) anion exchange resin tanks or organic scavenger tanks remove organic material, and (e) reverse osmosis membranes and its pump, where hydraulic pressure overpowers the osmotic pressure allowing pure water passes through the membrane free from salts, metals, and organic contents, such as bacteria, viruses and endotoxins.43

Figure 6. Components of water treatment station.

Haemodialysis prescription

The adequate prescription of HD session includes (1) duration (time) and frequency (how many sessions per week) of dialysis treatment, (2) dialyzer (type, surface area, KoA, Kuf) (3) blood and dialysate flow rates, (4) temperature, (5) ultrafiltration (volume of fluid removal), (6) anticoagulation (type, dose, administration, heparin-free HD), and (7) prescription of medications.

Duration and frequency of dialysis

Conventional HD prescription, using low- or high-flux dialyzers, is of 4 hours duration three times per week (12 hours/week). Sessions of less than 4 hours duration are associated with increased risk of mortality by 42%,47,48 and skipping at least one dialysis session is associated with a 25–30% increase in the risk of death.49 The frequency or duration of dialysis maybe increased to optimize fluid and solute removal.50 Increasing the frequency by short daily dialysis (e.g., 2-2 ½ hours) showed significant improvement in clinical outcomes.51–53 Increasing the duration of dialysis, independent of blood or dialysate flow rates, to 8 h has been associated with reduction in mortality and significant improvement in the clearance of small solutes (including phosphorus and uric acid) and middle molecules (marked by improvement in β2-M removal), and to a much lower extent the clearance of protein-bound uremic toxins.15,54 Nocturnal HD (overnight HD over 6-8 hours), where both duration and frequency can be increased, allows for smooth and gentle removal of uremic toxins and excess fluid over longer duration resulting in improvement in the washout feeling (post dialysis recovery time) and intradialytic hypotension episodes.53 Nocturnal HD has also been shown to provide an improvement in fluid status with better control of blood pressure,51,53,55,56 significant reduction in antihypertensive medications and left ventricular mass index.51,53,55 Furthermore, nocturnal HD led to significant improvement in renal anaemia,57 reduction in erythropoietin dosage and iron supplements,58 significant reduction in phosphorus binders,59 improvement in nutritional status,60,61 enhanced quality of life,62 and increased cumulative survival rate52 in a manner similar to that of deceased kidney transplantation.63 Increasing the duration and frequency of HD maybe best implemented in a home HD program, where patients benefit from the convenience of the time and duration of dialysis. However, implementation of daily/nocturnal HD has not been implemented on a large scale due to multiple reasons. These include logistic problems, conservatism by physicians and nurses, patient worries, and concerns of extra expenses.52 However, cost savings could be achieved by significant reduction in transportation, frequency of hospitalization, and extended use of dialyzers and tubing, and decreased waste production.62,64.65

Dialyzer

The performance of a dialyzer depends on its (a) mass transfer – area coefficient (KoA), which is the maximum capacity to remove a specific solute (usually urea) at a given flow rate, (b) coefficient of ultrafiltration (Kuf), which is the permeability to water – indicating how much fluid can be removed per unit of pressure applied, (c) molecular weight retention onset (MWRO), which is the molecular weight beyond which the membrane retains 10% of solutes, and (d) molecular weight cutoff (MWCO), which is the molecular weight (MW) beyond which the membrane retains 90% of solute.24

There are different types of dialyzers. These include low-flux, high-flux, medium cut-off, and high cut-off membranes. Low-flux dialyzer is characterized by its small pores (1.8-3.1 nm), and ultrafiltration coefficient (Kuf) of less than 15 ml/h/mmHg and clearance of beta-2 microglobulin (β2-M) less than 10 ml/min. It’s restricted to the removal of small molecules of less than 500 Da due to its low hydraulic permeability.24,66

High-flux dialyzer is characterized by its larger pore size (3.3-3.9 nm), where it provides ultrafiltration coefficient (Kuf) of more than 15 ml/h/mmHg and clearance of middle size molecules (e.g., β2-M) more than 20 ml/min, due to its higher hydraulic permeability.24,66

The medium cut-off dialyzer has larger pore size (5.0 nm) and is characterized by narrower hollow-fiber lumen (180 µm) and reduced thickness of the hollow-fibers (35 µm), which allows for internal diffusion and convection and the ability to remove large middle molecules (25-50 kDa), while retaining essential proteins like albumin.24,67,68

The high cut-off dialyzer has much larger pore size (10.0 nm), which enables the removal of the larger size molecules faster (up to 65 kDa), but on the expense of losing essential components like albumin. High cut-off dialyzers have limited use in certain diseases, like multiple myeloma (removal of kappa and lambda free light chains), for a short period (2-3 weeks) with the need of replacement of albumin.69

Other types of dialyzers include specially designed membranes to be prescribed in certain clinical condition, such as the internally grafted heparin dialyzers. This type of dialyzer is used alone70 or in conjunction with minimal systemic anticoagulation71 or citrate-containing dialysate72 to dialyse patients at risk of bleeding and those who are in need of heparin-free HD. Another special type of dialyzer is internally coated with vitamin E to reduce oxidative stress and inflammation. It has also been shown to alleviate erythrocyte deformability dysfunction in HD patients and provide anticoagulant activity.73

Blood and dialysate flow rates

Efficient blood flow rate is around 350-400 ml/minute, where the usual dialysate flow rate is about 500 ml/minute.74 The efficient clearance of small molecules is directly proportional to the blood flow rate,74–76 whereas larger size molecules require longer dialysis time.77–79 Achieving higher blood flow rate depends on a successful vascular access, as in mature and properly functioning AVF. CVC may not provide adequate or efficient blood flow rate. CVC may also affect the adequacy of dialysis by its local recirculation between the ports, and its association with increased risks of infection (bacteremia and sepsis), and clotting.40 Dialysate flow rate should be twice the blood flow rate. However, in practice, 1.5 times of blood flow rate is adequate – usually 500 ml/minute. Modern HD machines can automate the dialysate and blood flow rates.

Temperature

Modern HD machines are equipped with a temperature control system, where temperature can be adjusted from 35°C-38°C. Recent studies showed that lowering temperature by 0.5°C to 1°C below the patient’s core temperature can lead to vasoconstriction and help in reducing intradialytic hypotension episodes70,81 and cardiac stunning.82,83

Ultrafiltration

Fluid retention/overload in patients on dialysis is common, and it has been associated with increased blood volume and cardiac output, which can result in hypertension, left ventricular hypertrophy, and consequently heart failure.84,85 Fluid overload has been significantly associated with greater risk of mortality, and the higher the fluid overload the increased risk of death.86,87 Ultrafiltration (UF) is referred to how much plasma water should be removed during the dialysis session that was gained between HD sessions. The targeted fluid removal (UF volume) should be assessed properly to avoid excessive removal of fluids and intradialytic hypotension episodes. Frequent episodes of intradialytic hypotension can lead to ischemic insults to myocardium (stunning) and other internal organs (e.g., brain), which can lead to functional and structural changes (e.g., cognitive impairment).88,89 The targeted water removal is based on the estimated dry weight (euvolemic weight). So, the targeted fluid removal is calculated by subtracting the pre-dialysis weight from the estimated dry weight, which is in kg (equals liters). Generally, UF should not exceed 10 ml/kg/hour, especially in patients with cardiovascular disease. Earlier studies showed that fast removal of fluids of more than 10 ml/kg/hour can lead to increase in cardiovascular and all-cause mortality.90 Modern HD machines determine the necessary UF based on the treatment duration. In patients with increased weight gain due to excessive drinking, especially in hot climate countries, may benefit from isolated ultrafiltration – blood flow through the dialyzer but without passing dialysate. This technique, which can be set on the HD machine as “UF” only and performed prior to initiation or at the end of the HD session, helps in providing better haemodynamic stability by avoiding intradialytic hypotension.

Anticoagulation

The blood coagulation system is triggered and activated by the contact of blood with foreign material (e.g., blood lines, dialyzer) in the extracorporeal circuit. In the absence of anticoagulation, clotting can be visible (macro-clotting) and lead to early termination of the dialysis session, or micro-clotting (intrafiber deposition) and results in reduction in the clearance of solutes. This is in addition to frequent alarms, inadequate dialysis, blood loss, and added costs.91 Anticoagulation strategies include (a) systemic anticoagulation, (b) regional anticoagulation, and (c) anticoagulant-sparing strategies.

Systemic anticoagulation covers the whole body, in addition to the extracorporeal circuit. This can be achieved by systemic administration of unfractionated heparin (UFH), low-molecular weight heparin (LMWH), or non-heparin anticoagulants. UFH, which has a short half-life, can be administered by continuous infusion or bolus injections. It inhibits antithrombin-mediated factors IIa/Xa, and its excess/overdose can be neutralized by protamine sulfate.92 UFH is contraindicated in patients with heparin-induced thrombocytopenia (HIT).93 Low-molecular weight heparin (e.g., enoxaparin, tinzaparin, and dalteparin) has long half-life and is given as a single bolus injection. It has preferential inhibition of factors Xa over IIa. It has no antidote, but protamine sulfate may have some neutralizing effect.94–96 Non-heparin anticoagulants (e.g., argatroban, danaparoid, fondaparinux) have a direct inhibitory effect on factor IIa. It has no heparin cross reactivity, and as such can be used in patients at risk of HIT. It has a long half-life, which requires activated partial thromboplastin time (aPTT)/activated clotting time (ACT) titration.92,97

Serine protease inhibitors (e.g., nafamostat) are synthetic anticoagulants alternatives to heparin. They act by inhibiting regional serine protease with a rapid onset and short half-life effects. More specifically, they block various proteolytic enzymes, such as thrombin, trypsin, and factor Xa. Nafamostat, for example, is beneficial in avoiding systemic anticoagulation (heparinization) in patients at high risk of bleeding and HIT.98,99 However, it’s costly with limited availability, but could be helpful in patients with liver failure.100

Regional anticoagulation covers the extracorporeal circuit by either (a) regional citrate anticoagulation (RCA) or (b) short half-life agents (e.g., nafamostat and epoprostenol). RCA depends on using citrate to chelate calcium, which is necessary, in the intrinsic and extrinsic pathways, for clot/fibrin formation.101 Citrate binds to calcium in 1:2 ratio and reduces the level of calcium ions in a concentration-dependent manner.102 RCA is performed by infusing citrate into the circuit before the blood reaches the machine to chelate calcium and prevent thrombin formation, which requires using dialysate devoid of calcium (figure 7). For prevention of systemic hypocalcaemia, calcium is infused into the circuit before the blood returns to the patient.103

Figure 7. Schematic demonstration of the regional citrate anticoagulation

Anticoagulant-sparing strategies are helpful in prescribing heparin free dialysis in patients at risk of bleeding. These strategies include (1) intermittent saline flushes, (2) continuous saline infusion (pre-dilution), (3) citrate-based dialysate, (4) regional citrate anticoagulation, (5) heparin coated membranes, and (6) combined strategies. The effectiveness of these techniques in avoiding or reducing extracorporeal (circuit) clotting is variable.

Intermittent saline flushes, the circuit on average needs to be rinsed every 30 min with 25–200 ml of saline into the arterial line. Saline flushes technique is helpful when used in combination with high blood flow rate (above 300 ml/min). However, this technique is hampered by multiple disadvantages. These include (a) ineffectiveness in total prevention of clotting, (b) ultrafiltration volume must be increased to remove extra fluid used for the flush, (c) it’s time consuming, as the circuit needs to be visually inspected by the nurse for signs of clotting and the pressures are monitored and recorded, (d) activated clotting times need to be monitored to guide the frequency of intervention, and (e) change of the circuit following clotting.104

Continuous saline infusion, where normal saline is infused, at a rate of 200 ml/hour, into the arterial line (pre-dilution) to minimise the possibility of clotting during the treatment. This technique aims at lowering the concentration of hematocrit, platelets, and coagulation factors in the blood and consequently reducing the risk of thrombus formation. The downside of this technique includes (a) dilution of the blood and reduction in the clearance of uremic toxins, and (b) increase ultrafiltration volume to remove the extra infused fluids. When compared with intermittent saline flushes, continuous saline infusion technique is more effective in alleviating clotting of the extracorporeal circuit.105,106

Citrate-based dialysate technique is based on replacing acetate-based dialysate with citrate in low concentration (1 mmol/L) to increase haemocompatibility by chelating calcium in the extracorporeal circuit. Different studies showed the efficacy of citrate-based dialysate on lowering clotting107,108 and increasing intradialytic aPTT.108,109 Citrate-based dialysate has also been shown to reduce the required dose of heparin by about 30%,109,110 without affecting systemic coagulation activation.109,111 This means the effect of citrate is limited to the dialyzer and that the inhibition of the coagulation cascade taking place only in the extracorporeal circuit.

Regional citrate anticoagulation technique is beneficial in avoiding systemic anticoagulation (heparinization) in patients at high risk of bleeding and HIT. In a prospective, randomized and crossover study three strategies of heparin-free HD were compared. These were RCA, intermittent saline flushes, and the AN69 ST dialyzer manually primed with heparin112 RCA completed the 4 hours successfully without clotting, but not in the case of intermittent saline flushes or AN69 ST dialyzer, where thrombin/antithrombin complexes were significantly (p<0.05) increased when compared with RCA. However, RCA requires well-trained teams and additional pumps for citrate and calcium infusion with regular monitoring of ionized and total calcium and other electrolytes.113 It’s also associated with increased risk of complications such as bleeding and electrolyte disorders (hypo- or hypercalcemia and metabolic alkalosis),103 which can lead to fatal arrhythmias, and maybe contraindicated in severe liver failure.114

Heparin-coated membrane is a dialyzer that originates from the AN69 hydrogel membrane,115 which its surface is treated (ST) with polyethyleneimine (AN69 ST) to avoid acute reactions.116 This results in a heparin adsorptive hydrogel membrane, where polyethyleneimine layer carries a positive charge that enables the binding of the negatively charged heparin. The implantation of heparin on AN69 ST dialyzer can be achieved either manually, by priming with heparin in normal saline prior to the heparin-free dialysis session, or by chemically coating its surface with heparin in covalent bonds.117,118 The latter technique stabilizes heparin chemically and biologically (does not leak), and the resultant ready to use dialyzer (EVODIAL) maintains its activity throughout the HD session.119,120 This is especially the case when compared with conventional intermittent saline flushes121 or continuous (predilution) saline infusion.122

There were two major studies that investigated the effectiveness of EVODIAL dialyzer. These are RHODES71 and HepZero70 studies. The RHODES study is a prospective, multicenter, international clinical trial designed to evaluate the reduction of the systemic heparin dose by using the heparin-coated membrane (EVODIAL dialyzer) in 45 stable HD patients. The primary objective was to measure the systemic heparin activity at the end of the HD session using the lowest successful heparin dose, without coagulation issues in the extracorporeal circuit. The secondary objective was to evaluate the rinse-back quality of the filter and blood lines. The results showed heparin dose was decreased by an average of 45% in 2/3 of patients without compromising the dialysis session. The dose reduction was achieved with both low molecular weight and unfractionated heparin. There was no massive clotting that led to premature stopping of dialysis session, and treatment with EVODIAL dialyzer was well tolerated. This effect was associated with 50% reduction in anticoagulation activity (anti-Xa).

The HepZero is a randomized controlled trial (RCT), which studied 265 stable HD patients in 10 centres from 7 countries (France, Spain, Belgium, Canada, Poland, UK, Netherlands).70 The primary objective was to assess the effectiveness of EVODIAL dialyzer in terms of first heparin-free session success. The secondary objectives include the success rates of the 2nd and 3rd consecutive heparin-free sessions, clotting grading in air traps (all sessions), and the heparin-free dialysis session efficacy. The results showed 18% significantly higher success rate in the group treated with the EVODIAL with longer duration of the HD session versus conventionally (saline flushes or blood predilution) treated controlled group. However, both RHODES and HepZero studies achieved 67% and 69% success rate, respectively. This indicates that there is about 30% failure rate with both approaches, and suggests a need for a combined strategy.

Combined strategy is a therapeutic approach to an effective heparin-free HD devoid of any extracorporeal clotting. An open-label randomized crossover noninferiority trial, in 25 HD patients, compared a heparin grafted membrane plus citrate-containing dialysate with RCA (CiTED; Citrate and EVODIAL). The primary endpoint was completion of dialysis without significant clotting, and secondary endpoints included time to clotting, venous air chamber clotting, and systemic ionized calcium concentration.72 There were 636 sessions in the CiTED group and 648 in the RCA-treated group. The preterm interruption due to clotting occurred in 36 (5.7%) of sessions in the CiTED arm, and in 40 (6.2%) sessions in the RCA arm, thereby meeting noninferiority criteria (P < 0.0001). Systemic-ionized calcium levels during treatment were significantly lower in the RCA arm and clinically relevant hypocalcemia was noted only in the RCA arm. These results showed the effectiveness of the combined approach in preventing clotting similar to that of standard RCA, and the combination of citrate-containing dialysate and a heparin-grafted membrane could be a valid alternative to RCA.

Vitamin E coated polysulfone has been shown to provide anti-inflammatory and anti-oxidative stress. In a systematic review and meta-analysis study, Vitamin E-coated dialyzer was capable of reducing C-reactive protein and IL-6, and some parameters of oxidative stress such as serum thiobarbituric acid reacting substances and oxidized low density lipoprotein.123 It has also been shown to alleviate erythrocyte deformability dysfunction in HD patients,73 and provide anticoagulant activity. In a multicenter, prospective, randomized, crossover study, Vitamin E coated dialyzer was evaluated and compared with EVODIAL dialyzer in a 4-hour heparin-free HD study.124 Thirty-two patients were randomly allocated to a first period using either vitamin E or EVODIAL. After a washout period of 2 HD sessions, each patient was switched to the alternative dialyzer for a second period. Each study period started with 2 HD sessions with reduced heparin dose (50% and 25% of usual heparin dose, respectively, for sessions 1 and 2) followed by 2 heparin-free sessions. The primary end point was the percentage of successful study periods, defined as no circuit-clotting event leading to premature interruption of any of the 4 dialysis sessions. Secondary endpoints included total number and cumulative duration of HD sessions without clotting, number of saline solution flushes, dialysis circuit bubble trap status and dialyzer membrane status by visual inspection, and dialysis adequacy. The resulted data showed the noninferiority of vitamin E-coated dialyzer to that of EVODIAL. There were equal numbers of clean dialysis circuits bubble traps in both dialyzers, but clean fiber bundles were more frequently noted with the vitamin E–coated dialyzers.

The asymmetrical triacetate dialyzer (Solacea-19H) pore structure, which limits contact activation with blood that leads to clotting, was evaluated in combination with either citrate dialysate or predilution HDF for heparin-free HD in the SAFE study.125 Data showed that both the citrate-containing dialysate and high-volume predilution HDF resulted in acceptable rates of clot-free dialysis when performed with the asymmetrical triacetate dialyzer.

Prescription of medications

It’s important to adjust the dose and timing of prescribed medications for HD patients due to the variability of their clearance or removal during HD.126 The clearance of different medications depends on multiple factors. These include (a) absorption, (b) molecular weight (MW), (c) hydrophilic or hydrophobic, (d) binding to proteins, and (e) tissue distribution and the post dialysis rebound effect.127 Advanced HD modalities (e.g., post-dilution online haemodiafiltration) may clear more of certain medications.128 However, most drugs are small molecules (<1,000 Daltons) and are excessively removed during HD.

Dialyzable medications need to be administered after the dialysis session.129 These include vancomycin, aminoglycosides, penicillins, cephalosporins, atenolol, and captopril. Whereas poorly dialyzable medications maybe given prior to HD session. These include anticoagulants, insulin,130 antiemetics, statins, warfarin, and proton pump inhibitors. Other non-dialyzable medications include carvedilol, losartan, amlodipine, digoxin, amiodarone, phenytoin, codeine, and benzodiazepines.131 However, it’s advisable to administer antihypertensive medications after the HD session to avoid intradialytic hypotension. Equally important, insulin injections need to be adjusted on HD days due to the shift of glucose in the dialysis fluid into blood. Medications that are usually given during HD session include erythropoietin, intravenous iron, intravenous vitamin D analogues, and phosphorus binders are given with meals irrespective of HD. Finally, it’s recommended to monitor therapeutic blood level/plasma concentration of certain medications, as with antibiotics like vancomycin and aminoglycosides.

Assessment of haemodialysis adequacy

The conventional method of assessing the dialysis adequacy is to measure the clearance of small solutes represented by urea. This can be achieved by measuring the urea reduction ratio (URR) before and after the dialysis session reaching to at least 65%, where 70% is the optimal target.132 Kt/V measures the fractional clearance of urea, where “K” stands for dialyzer urea clearance, “t” is dialysis time, and “V” is the volume distribution of urea, which is equivalent to patient's total body water. The target of single pole Kt/V (spKt/V), for conventional thrice-weekly HD, should be a minimum of ≥ 1.2 per session (1.4 is the optimal, especially in females and small men),133,134 while the equilibrated Kt/V (eKt/V), which accounts for post dialysis urea rebound (urea takes time to equilibrate from the intracellular to the extracellular space) should be ≥ 1.05.135 The HD prescription should be increased if Kt/V is low. This can be achieved by increasing the treatment time and/or frequency, blood or dialysate flow rates, or using a dialyzer with a larger surface area.74,136 However, Kt/V does not represent the clearance of middle or large middle molecules (e.g., α-1 microglobulin, kappa and lambda free light chains, and YKL 40), which have been associated with inflammation, arteriosclerosis, and vascular calcification, all of which can lead to increased risk of cardiovascular morbidity and mortality.137,138

Advanced haemodialysis modalities

Uremic toxins

Over the past 50 years, conventional (low-flux and high-flux) HD has been associated with reduction in mortality rate,139 and in recent years, there has been slight incremental improvement in survival rate.140 However, longterm outcomes in conventional HD are still unsatisfactory. Patients are often inflammed, malnourished, and anaemic. Quality of life and rehabilitation are suboptimal (e.g., impaired physical function, poor recovery time, pruritus, and restless leg syndrome), and cardiovascular and all-cause mortality remain unacceptably high.141–143 These clinical outcomes have been associated with the retention of a wide spectrum of molecules in the blood,144 which are not fully corrected due to insufficient cleansing. High level of such molecules (uremic toxins) correlate with these outcomes.145,146

A recent expert consensus conference classified uremic toxins, based on their physicochemical characteristics, dialytic removal, and linkage to clinical symptoms and outcomes, into (a) small molecules of less than 500 Da, such as urea (60 Da) and creatinine (113 Da), (b) small middle molecules of more than 500 Da but less than 15,000 Da (15 kilo Da), such as parathyroid hormone (9.4 kDa) and β2-M (11.8 kDa), (c) medium middle molecules between 15 kDa and 25 kDa, such as myoglobulin (17.7 kDa) and kappa free light chains (22.5 kDa), and (d) large middle molecules above 25 kDa, such as α1-microglobulin (α1-M of 32 kDa), fibroblast growth factor-23 (FGF-23 of 32 kDa), and lambda free light chains (45 kDa).147 There are also protein-bound uremic toxins, which are small-size uremic toxins below 500 Da, but are difficult to remove because they are bound to proteins such as indoxyl sulfate (108 Da) and p-cresyl sulfate (251 Da). Inadequate removal, and retention, of these uremic toxins by conventional HD, especially the larger size molecules, have been associated with inflammation, atherosclerosis and vascular calcification,146 all of which increase the risk of cardiovascular disease and death (table 1).

Table 1. Association between retained uremic toxins and clinical outcomes.

Uremic toxinClinical association
Beta 2 Microglobulin (β2-M: 11.8 kDa)HD-related amyloidosis, including bone cysts and carpel tunnel syndrome, increased risk of cardiovasculr events and mortality rate.148,149
Fibroblast Growth Factor 23 (FGF-23: 32 kDa)Vascular calcification, left ventricular hypertrophy, increased risk of cardiovasculr events and mortality rate.140–152
Alpha 1-microglobulin (α1-M: 32 kDa)Restless leg syndrome.153,154
YKL-40
(glycoprotein produced during inflammation, cell growth, and tissue remodelling: 40 kDa)
Endothelial dysfunction, vascular calcification, and increased risk of mortality.155
Kabba (22.5 kDa) and lambda (45 kDa) free light chainsInflammation (decreasing chemotaxis by neutrophils, inhibiting spontaneous PML apoptosis, and associated with increased levels of IL-6 and CRP), aortic calcification, and increased mortality.156,157
Protein-bound molecules (Indoxyl sulfate: 251 Da and p-cresyl sulfate:108 Da)Atherosclerosis, increased risk of cardiovascular and all-cause mortality.158,159

When high-flux dialyzer was created, the aim was to remove the retained middle size molecules that cannot be removed by low-flux dialyzer. These include β2-M (11.8 kDa), which is considered as a surrogate marker for middle molecules that is strongly associated with carpal tunnel syndrome and HD-related amyloidosis. High-flux dialyzer was capable of removing β2-M efficiently, but larger molecules (e.g., myoglobulin of 17 kDa, complement factor D of 27 kDa, and proinflammatory cytokines of variable MW) were inefficiently removed.160 The clearance of uremic toxins by conventional (low- and high-flux) HD is based mainly on diffusion, which is quite efficient in removing small soluble molecules. This limitation of inability to remove the larger size molecules left a wide gap between the kidney function and the HD replacement therapy. Earlier studies showed that diffusion is insufficient in removing larger size molecules (uremic toxins), but convection is mandatory and more important for their clearance.161 Advanced HD techniques, such as haemofiltration, haemodiafiltration, and expanded HD, do implement convection.162

Haemofiltration

Haemofiltration (HF) is a dialysis therapy that is based on the implementation of the physiological principle of convection, but without passing dialysate (devoid of diffusion). The imposed pressure gradient across the semipermeable high-flux membrane allows blood inflow to filter lots of water and dissolved larger size uremic toxins (e.g., proinflammatory cytokines). The excessive ultrafiltration and loss of fluids require replacement of sterile (ultrapure) solutions infused directly into patient’s bloodstream to maintain fluid and electrolytes balance (figure 8). This technique, with or without haemoperfusion, is mostly prescribed in intensive care units for critically ill patients, such as those with acute kidney injury and sepsis, and multi-organ failure.163–165

Figure 8. Demonstration of haemofiltration technique.

Haemodiafiltration

Haemodiafiltration (HDF) therapy is a combination of haemodialysis (HD) and haemofiltration (HF) using high-flux dialyzer, where both physiologic principles of diffusion (passing dialysate) and convection (excessive ultrafiltration) are applied, thereby clearing small and larger size uremic toxins, respectively.166,167

The value of online HDF is in its ability to implement the physiological principle of convection by excessive ultrafiltration under pressure, which results in the removal of larger size molecules together with fluids. To maintain fluid balance, fluid replacement is essential in the form of convective volume (figure 9). Convective volume is defined as the total amount of fluid that moves across the dialysis membrane for convective clearance. It includes the substitution volume (the replacement fluid of excessive ultrafiltration) plus the net ultrafiltration volume (the fluid removed to achieve the patient's dry weight). The total replacement of fluids can be administered before (pre-dilution) or after the dialyzer (post-dilution), or administered as mid-dilution or mixed dilution (table 2). There is variable concentration clearance of uremic toxins with different effects on albumin loss, clotting of the filter, and transmembrane pressure (table 2). In clinical practice, the most prescribed mode is the pot-dilution HDF.168–171 The replacement fluids used to be sourced from commercially prepared sterile fluid bags hanged next to the HD machine, which requires 1 - 3 liter bags/hour. In addition to the cost of this approach, the limitation of replacement fluid volume per session, availability of adequate storage, and the weight and hassle abolished this method. The development of advanced water treatment stations/plants, which can provide ultrapure water instantly and in large volume (25-60 L/session) and in an unlimited supply, contributed to the practical implementation of online HDF.172,174 The worldwide prevalence of HDF varies significantly.173 Earlier assessment showed it’s about 10%,175 but more recent registries data showed that HDF is mostly prevalent in Europe and Asia Pacific with a growth rate between 12%-24%.176 This variation is due, at least in part, to the healthcare regulations and reimbursement policies and the strength of medical/real-world evidence.177

Figure 9. Demonstration of haemodiafiltration technique.

Table 2. Site of fluid reinfusion166–168, 171.

Post-dilutionPre-dilutionMixed-dilutionMid-dilution
Small solute clearance+++++++++
Medium solute clearance+++++++++
Protein-bound solute clearance++++++++
Albumin loss+++++++
Filter clotting+++++++
High TMP+++++++

Prescription and requirement. Like conventional HD, HDF is usually prescribed 4 hours per session three times per week. However, HDF requires (a) specially designed HD machine equipped with specific features to safely prepare dialysate (mixing acid and bicarbonate concentrates) and infuse replacement fluid, by installed second pump, and control fluid balance. The HD machine is also equipped with sterilizing ultrafilters to ensure the purity of dialysate and infused replacement fluid,171 (b) large surface area dialyzer (e.g. high-flux of 2.1 m2) that sustains high transmembrane pressure (TMP). The TMP is defined as the net hydrostatic pressure difference across the dialyzer membrane. If manually adjusted, it should be <400 mmHg with a filtration fraction <0.25, and between 105-300 mmHg if automated,168 (c) higher blood flow rate (≥350 ml/minute delivered by properly functioning vascular access using a fistula needle of 14 or 15 gauge), (d) dialysate flow rate varies from 500-600 ml/minute, (e) water treatment station that produces ultrapure water for dialysate preparation, and (f) systemic infusion of large volume of substitution fluid (≥ 23 L/session/1.73m2 or 55-75 L/week) to maintain fluid and electrolytes balance.178,179 Adequate prescription allows for efficient removal of different sizes of uremic toxins, especially the larger size molecules. For example, β2-microglobulin, as a surrogate marker for middle molecules, and larger size molecules, have been shown to be more efficiently removed by online HDF than high-flux dialyzers.170,180

Clinical outcomes. Inflammation. Patients with end-stage kidney disease and on HD are at increased risk of systemic inflammation.181 This is due, at least in part, to the retention of several types and sizes of proinflammatory uremic toxins (including proinflammatory cytokines), microbiological quality of dialysis water, vascular access (especially central venous catheters), biocompatibility of dialysis membranes, poor nutrition, and infection.182,183 HDF treatment has been associated with significant reduction in inflammation. This was attributed to its convective ability in removing large-size inflammatory molecules184 and the use of ultrapure water.173,185 This was evident by the significant reduction of C-reactive protein (CRP) and IL-6,186–190 and lowering oxidative stress (e.g., reactive oxygen metabolites)191 and increasing the anti-oxidative capacity.192

Haemodynamic stability. Haemodiafiltration has been found to provide better haemodynamic stability than conventional HD by significant reduction of intradialytic hypotension episodes.193 This effect is most likely driven by the negative thermal balance.194

Patients’ satisfaction and quality of life. In a previous RCT over 24 months, high-efficiency post-dilution online HDF versus high-flux HD significantly improved patients’ satisfaction and quality of life. These included social, physical, and professional activities, body energy, dialysis compliance, sexual performance, general mood, taste, and appetite. These effects were associated with significantly less episodes of hypotension, cramps, itching, general and post-dialysis fatigue, and joint pain and stiffness.170 In the recent CONVINCE RCT, which compared high dose online HDF with conventional HD over a period of 30 months, showed a statistically significant improvement in the physical health and cognitive function.195 Earlier studies have also showed significant improvement in patients’ satisfaction and several parameters of quality of life,196–200 and Maduell et al.201 reported a remarkable improvement in nutritional status with adequate social and occupational rehabilitation in patients treated with on-line HDF. However, other studies could not find a difference in daily quality of life between online HDF and high-flux HD.202–204

Survival (cardiovascular and all-cause mortality). Convective volume has been linked, as a surrogate marker, to the survival of patients on HDF.205 Earlier RCT, which included the CONTRAST study,206 Turkish study,207 ESHOL study,208 and the French study (DOPPS),209 as well as the combination of data of these studies,210 showed that a convective volume of ≥ 23 L/session/1.73m2 or 55-75 L/week (table 3) has been associated with 31% reduction in cardiovascular mortality and 22% in all-cause mortality.178,179 However, these findings were not confirmed by the Cochrane systematic review of RCTs211 and the “real-world” HD comparison DOPPS study.212 More recently, however, the CONVINCE large RCT, which compared high dose online HDF with conventional HD over a period of 30 months, showed a significant reduction in mortality risk (17.3% versus 21.9%, p<0.005).195 These findings were also associated with significant improvement in the physical health (p=0.035) and cognitive function (p=0.031). A recent Brazilian retrospective cohort study comparing online HDF with high-flux HD in 29 HD clinics over a period of 2 years showed a significant reduction in death risk (HR, 0.73 [95% CI, 0.63-0.85). The 2-year survival rates in these groups were 81.2% and 77.9%, respectively (P<0.001). HDF treatment was also associated with a reduction in cardiovascular mortality risk, but not in infection-related death.213 More recently, a large multinational target trial emulation found that sustained high-volume post-dilution HDF was associated with lower mortality than high-flux haemodialysis.214

Table 3. Convective volume required to achieve a reduction in cardiovascular and all-cause mortality.206–210

StudySubstitution VolumeConvection VolumeRR or HR (CI)
DOPPS209>15 L / session>17.5 L / session0.65
CONTRAST206>19.45 L / session>21.95 L / session0.61 (0.38-0.98)
TURKISH OL-HDF207>17.4 L / session>19.9 L / session0.54 (0.31-0.93)
ESHOL20820.6-22.9L / session23.1-25.4 L / session0.60 (0.39-0.90)
>22.9L/session>25.4L/session0.55 (0.34-0.84)

Implementation of online HDF. Despite its effectiveness in improving the clinical outcomes, achieving efficient online HDF prescription requires significant investment in its setting up. This includes (a) a double pump HD machine (usually more expensive than single pump HD machine), (b) advanced water treatment plant/station that produces ultrapure water (more expensive than the standard water treatment stations), (c) regular monitoring and testing the quality of water, (d) consumption of additional volume of water (30% more than conventional HD), (e) functioning vascular access that delivers at least 350-400 ml/minute – maintaining properly functioning AVF may require hospital admissions and surgical interventions, (f) training of staff – could be a challenge in high staff turnover dialysis clinics, and (g) achieving prescribed convective volume, which depends on several patient- and treatment-related factors. These include blood flow rate of > 350 ml/min (properly functioning vascular access), 14–15-gauge fistula needle, treatment time, characteristics of the dialyzer (e.g., membrane surface area, UF coefficient, capillary dimensions), hematocrit, serum albumin, and dialysis interruptions time. Control and implementation of these factors can help in achieving a convective volume/dose of ≥ 23L/ session/1.73m2. Achieving this convective dose in daily clinical practice is challenging.170,206,207,215,216 An earlier study found that HDF cannot be considered a cost-effective treatment for patients with end-stage renal disease.217 A recent simulation study, however, showed the cost-effectiveness of online HDF when compared with high-flux HD.218 More recently, the cost-effectiveness of HDF was compared to high-flux HD using the Markov cohort model, and based on the improved survival rate that was concluded from the CONVINCE study.194 The probability of cost saving was mainly driven by the additional dialysis sessions in life years gained, and not due to additional costs per dialysis session.219

Expanded haemodialysis

Medium cut-off dialyzer. Recent innovation in dialyzer technology led to the development of the medium cut-off (MCO) membrane with improved biocompatibility and its availability in two surface areas (1.7 and 2 m2).68 This is a new class of membranes for dialysis, beyond conventional high-flux membranes. It is composed of two polymers: polyarylethersulfone (PAES) and polyvinylpyrrolidone (PVP). The PAES is a hydrophobic polymer that provides mechanical and thermal properties, together with adsorptive properties for bacterial degradation products (e.g., lipopolysaccharides). The PVP is a hydrophilic polymer that provide wettability, pore formation, and solute transport properties.68 Unlike high-flux membrane, the MCO membrane has narrower pore distribution and larger size pores (pore radius of 5 nm versus 3.9 nm), less wall thickness (35 µm versus 50 µm) and narrower lumen (180 mm versus 210 mm).68,220 The reduced wall thickness allowed for better diffusion (less resistance), and the narrower lumen allowed for powerful arterial pressure leading to internal convection in the first part of the hollow fibers resulting in effective clearance of larger size uremic toxins. As the blood reaching the terminal part of the hollow fibers the arterial pressure is significantly reduced resulting in internal/back filtration, due to the higher dialysate pressure entering at the other end of the dialyzer.221 Experimental studies showed that the MCO dialyzer is capable of delivering internal convection of 30-53 ml/min based on blood flow rate, which is equivalent to 7.2-12.7 liter of convective volume per 4 hours session.222 These characteristics allowed for adjustment between the molecular weight retention onset and molecular weight cut-off of the membranes, and resulted in better clearance of the large medium uremic toxins (25–58 kDa) with preservation/limitation of albumin loss.223 This type of dialyzer can be used on any regular single pump HD machine. Efficient clearance of small and large sizes uremic toxins can be achieved at blood flow rate of ≥300 ml/min, though some studies showed 250 ml/minute is adequate,224 and dialysate flow rate of 400-500 ml/min.225 Conventional treated water/dialysate (bacterial growth < 100 U/ml, and endotoxin < 0.25 EU/ml) can safely be used.226,227 The adequate internal/back filtration (about 12 Liters) compensate for the ultrafiltration without the need for fluid replacement. This modality of HD is called expanded haemodialysis (HDx).228

Clearance of uremic toxins. The structure and design of the MCO membrane allow for diffusion and convection to take place internally. Kirsch et al.32 compared the effectiveness of MCO dialyzer with high-flux HD and post-dilution online HDF on the clearance of small and large-size molecules. They showed almost similar clearance of small molecules among these modalities. However, the MCO membrane showed significantly higher clearance of the larger size molecules, including myoglobin, pro-inflammatory cytokines and lambda free light chains. These findings were confirmed in multiple randomized control studies224,229–232 and in a meta-analysis and systematic reviews.233,234

Safety. Albumin loss. Albumin has a MW of approximately 67 kDa, and is considered the most important protein in blood that maintains intravascular colloidal oncotic pressure. During inflammation and infection, the liver is stimulated to release acute phase reactants (e.g., IL-6, ferritin, C-RP, and serum amyloid A) and a decrease in albumin synthesis (a negative a cute phase reactant).235 Normal serum level of albumin is above 3.5 g/dl, though lower mortality rate has been associated with levels above 4 g/dl.236 Lower serum albumin levels (<3.5 g/dl) have been associated with inflammation, malnutrition, and increased risk of death.236 There is no consensus on how much daily loss of albumin is acceptable, but studies have shown that a weekly loss of <12g of albumin may have less risk.68,237 It has also been recommended to avoid albumin loss of >5g/session.238 The albumin loss in patients on conventional high-flux haemodialysis varies between 0-2 g/session, depending on the dialyzer used (material and surface area).239,240 Patients on peritoneal dialysis have been known to lose in their dialysis fluid (effluent) at least 5 g of albumin per day, which is compensated by hepatic synthesis.241 The normal hepatic synthesis of albumin varies, but it’s about 10.5 g/day.235,242

The efficient clearance of large middle molecules through the larger pores of the MCO dialyzer, and the proximity of its cut-off molecular weight to that of albumin brought early concerns about significant loss of albumin. Studies by Storr and ward,68 showed an insignificant loss of albumin that varies between 2-4 g/session, which may not affect the nutritional status, especially in well-nourished HD patients.237,243 Other studies observed a range of 1.9 to 3.2 g (average 2.1 g) of albumin loss per 4 hours session.32,244–247 Two RCTs compared patients treated with MCO dialyzer with those treated with high-flux dialyzer over six months. Both studies showed stability of serum albumin.229,232 A large cohort study comparing MCO dialyzer with high-flux in 992 patients over 12 months showed slight reduction in albumin (- 1.2%) from baseline.248 In another cohort study comparing MCO dialyzer with high-flux dialyzer in 1098 patients over 2 years also showed similarity and stability of serum albumin above 4 g/dl.249 More recently, a large cohort study comparing MCO dialyzer versus high-flux over 4 years confirmed the stability of serum albumin.250

Likewise, the loss of albumin in patients on online HDF is variable with an average of 3.134±2.450 g/session.237 In a smaller study, the average loss of albumin was 1.82+1.05 g/session.243 The variation of the amount of albumin loss in patients treated with online HDF depends on the permeability of the dialyzer, increased transmembrane pressure, and high convective volume.237,251 Significant albumin loss with severe hypoalbuminemia have been reported with the use of highly permeable high-flux dialyzers.251 In an earlier pilot RCT comparing MCO dialyzer with online HDF showed a moderate albumin loss with the MCO membrane, but greater than that of online HDF.32 Later studies showed the average amount of albumin loss (2.29 ± 0.99 g) was not different between patients treated with the MCO dialyzer and those treated with 8 different membranes in post-dilution online HDF.244

It has been suggested that losing some (bad) albumin may help in clearing protein-bound uremic toxins.252 Protein-bound uremic toxins (e.g., indoxyl sulfate and p-Cresyl sulfate) have small molecular weight (<500 Da), but because they are bound to protein it’s quite difficult to remove them by different dialysis techniques. They have been associated with severe endothelial inflammation and vascular calcification in experimental studies,253 as well as increased cardiovascular and all-cause mortality in clinical studies.253–256 An observational Japanese study over 7 years aimed at analyzing the association between albumin leakage with mortality. The investigated 690 HD patients were divided into three groups based on the amount of albumin loss in dialysate: large (≥ 3 g), middle (1 - 3 g), and small (< 1 g). A propensity score analysis was performed to the three groups according to albumin loss per HD session.257 This study showed that albumin leakage ≥3 g/session provided better prognosis (lower death rate) than albumin leakage <3 g/session. These results were confirmed in a retrospective observational study over 3 years.258 In this study, a propensity score-matched model was developed to compare 355 stable patients on super high-flux (defined by its ability of clearing β2-M by ≥ 50 mL/min) with 428 stable patients on online HDF. Data showed that all-cause mortality was significantly lower in patients with higher estimated albumin leakage, independent of the HD modality. These data suggest that small amount of albumin loss is protective against mortality among HD patients.

Endotoxins. The quality of water and dialysate for HD is of vital importance to prevent any adverse events such as pyrogenic reactions, infections, and severe inflammation. The larger pore size of the MCO membrane and its effective internal convection raised concerns regarding the possibility of passing bacteria and endotoxin into the blood compartment should the water/dialysate be contaminated.

Earlier studies showed that dialysis membranes that are made of hydrophobic polymers have effective adsorptive capacity for endotoxins.259,260 The structure of the MCO membrane includes the hydrophobic polymer polyarylethersulfone, which provides adsorptive properties for bacterial degradation products (e.g., lipopolysaccharides).68 In vitro studies, using standard methods to measure bacteriological contamination of the dialysate (bacterial culture, the Limulus Amebocyte Lysate assay, and THP-1 biological assay for the generation of IL-1β)261 and testing different dialyzer membranes (low flux, high flux, MCO, and high cut-off) assessed the capacity of these membranes to retain endotoxins.262,263 A simulated treatment through a dialysis circuit significant amount of endotoxins (nearly 10 times the assumed maximum allowable endotoxin load) was loaded onto the dialysate side and levels of peptidoglycan, lipopolysaccharide and bacterial DNA were measured on the blood side after simulated dialysis. The results showed that the retentive capacity of the MCO and high cut-off membranes were much higher for lipopolysaccharide in comparison with low-flux and high-flux membranes, as well as the absence of interleukin-1 beta (IL-1β) generation.264 This indicates that MCO dialyzer has high retentive capacity and low permeability to endotoxins, as the low-flux and high-flux membranes, and prevented passage of bacteria and byproducts such as endotoxins from the dialysates with multiple magnitude loads of contamination. The authors concluded that MCO membranes are suitable for HD using ISO conventional/standard dialysis fluid quality and retain endotoxins at a similar level as other membranes. In vivo multicenter retrospective observational study (1,098 patients), 564 (51.3%) patients were dialyzed with MCO membranes and 534 (48.7 %) with high flux membranes. All treatments were performed using the water-quality standards established by the Association for the Advancement of Medical Instrumentation for conventional dialysis water and dialysate. Patients who were dialyzed with MCO membranes had a lower all-cause hospitalization incidence rate per patient-year compared to those who were treated with high flux.232 Clinical outcomes were reproduced in a similar study.249 Real-world data showed that serum albumin level was similar between the two treatment groups, and there was significant reduction in hospitalization (-18%) and non-fatal cardiovascular events (-34%) in patients treated with MCO compared to high flux.

These in vitro and in vivo studies showed that MCO dialyzer provided markedly effective barrier and very high margin of safety against microbial contamination. This was reflected by the maintenance and stabilization of serum albumin, significant reduction in inflammation, improvement in hospitalization, and decrease in non-fatal cardiovascular mortality, all of which indicate the safety use of MCO dialyzer.

Prescription of medications. In vitro studies compared the retention of commonly prescribed medications of various molecular weight between MCO with polysulfone high-flux dialyzers used in HDF, and polyethersulfone membranes used in HD and HDF.265 These include erythropoietin (30 kDa), low-molecular-weight heparin (LMWH; 5 kDa), insulin (6 kDa), and vancomycin (1.5 kDa). The retention of large coagulation factors was also investigated, including factor II (71.6 kDa), factor VII (50 kDa), factor X (58.8 kDa), protein C (62 kDa) and antithrombin III (ATIII; 58 kDa). Results showed that there was no difference in the retention of these molecules and were comparable between MCO membrane and the high-flux dialyzers.266

Clinical studies comparing MCO with high-flux dialyzers used in conventional HD and online HDF showed similar prescribed doses of unfractionated229,248,267 and low molecular weight heparin.267,268 These data suggest that there is no need to adjust the dose of these medications when using the MCO dialysis membranes. However, higher doses of anti-coagulants may be required if a higher surface area dialyzer is prescribed.229,248 In addition, despite the lack of significant statistical difference in vancomycin clearance between high-flux HD and HDx enabled by MCO dialyzer, there was a significant drop in vancomycin levels 2 hours after starting the sessions of both HD modalities.270 It was suggested to add vancomycin during the last 1-2 hours of each high-flux HD or HDx session to maintain therapeutic concentrations and minimize loss through the dialyzers.

Clinical outcomes. There has been an increasing body of evidence on the benefits of the MCO membrane on different aspects of the clinical outcomes. These include inflammation, vascular calcifications, residual kidney function, nutritional status, different parameters of quality of life, hospitalization, cardiovascular and all-cause mortality.

Inflammation. Expanded haemodialysis (HDx) enabled by the MCO membrane, when compared with high-flux HD, has been shown to be more efficient in purifying blood from uremic toxins and inflammatory mediators. These include significant reduction in kappa and lambda free light chains, C-reactive protein,271,272 messenger RNA expression of TNF-α and IL-6,273,274 and drop in blood levels of TNF-α, IL-1β, and IL-6 in patients with acute kidney injury and septic shock.275 These effects were associated with amelioration of systemic microinflammation and endothelial dysfunction.274

In a prospective cross-over pilot study, Cozzolino et al.276 studied infective episodes, that required antibiotics, in patients treated with MCO membrane versus patients on high-flux HD. Data showed significant reduction in the number of infective episodes in patients treated with the MCO membrane, but non-significant trend in related hospitalization. This effect was associated with lower blood levels of IL-1β and IL-6 (no change in TNF-α), without hypoalbuminemia or significant change in hypotensive episodes.

Vascular calcification. In vitro studies showed the ability of the MCO membrane therapy in chronic HD patients to prevent calcification and apoptosis of vascular smooth muscle cells.277 In a prospective open label, controlled, cross-over study, the pro-calcifying effect of the uremic serum collected from patients treated with either MCO membrane or high-flux HD was incubated with blood vessels of a rat model of high phosphate-induced calcification in vascular smooth muscle cells (VSMC). The data of this study showed a tendency of less pro-calcifying potential and less VSMC necrosis from MCO-treated patients’ serum compared with high-flux HD.278

Residual kidney function. A recent multicenter, open-label, prospective RCT studied the effect of HDx enabled by Theranova dialyzer on the preservation of residual kidney function (THREAD Randomized Controlled Trial). Eighty incident HD patients were randomized to Theranova versus high-flux HD over 12 months. Results showed a significant smaller decrease in GFR and higher urine volume (at 9 months) in the HDx group when compared with the high-flux treated group.279 This was accompanied by significant reduction in β2-microglobulin and higher reduction ratio for larger size molecules, including TNF-α, and kappa and lambda free light chains. However, there were no differences in hospitalization rate or mortality between the two groups.

Quality of life. Patients on conventional HD suffer from mild to severe reduction in different parameters of physical and mental functions.280 These include poor mobility, weakness/lack of energy, itching, sleeping difficulty, delayed post HD recovery time, and restless leg syndrome.281–284 There are several contributing factors that may influence the quality of life in HD patients. These include retained proinflammatory molecules (especially large-size uremic toxins and proinflammatory cytokines), comorbid diseases, anaemia, and poor nutritional status.285 Treatment of high-flux HD patients with the MCO membrane showed beneficial effects on their quality of life.286 Improvements were noticed in post HD recovery time,287,288 restless leg syndrome,287–289 itching,287,290,291 and physical and mental status.288,289,291 Some of the studies, however, are observational and retrospective, of small sample sizes, and short follow-up durations.

Cardiovascular outcomes and Hospitalization. In a large retrospective observational multicenter cohort study, patients treated with the MCO membrane (n=564) versus patients treated with high-flux HD (n=534) and followed up for 2 years showed statistically significant reduction in hospitalization rate by 18% and non-fatal cardiovascular outcomes by 34%.249 In a post hoc evaluation of a randomized clinical trial, MCO membrane treated patients had 45% significant drop in all-cause hospitalization, with an estimated annual cost reduction of $6098 versus the high-flux treated patients.292 A multicenter observational cohort study showed that patients treated with MCO membrane had significantly lower hospital days per patient-year than those treated with high-flux dialyzer.293 This was associated with significantly lower consumption of medication, especially in erythropoietin dose. This was confirmed by a RCT, where MCO membrane-treated patients showed statistically lower needed doses of erythropoietin. This was coincided with significantly lower erythropoietin resistant index four weeks after starting treatment with MCO membrane versus patients treated with high-flux dialyzer.294 This may reflect the significant amelioration of inflammation.

Survival outcomes. Like online HDF, expanded HD enabled by the MCO membrane showed survival benefits over conventional HD enabled by high-flux dialyzer. In a multicenter, retrospective cohort study, 559 patients were treated with HDx therapy and compared with 533 patients treated with conventional high-flux HD. Both groups were followed up over 4 years. Patients treated with the MCO dialyzer achieved 21% reduction in the risk of death, despite the significant prevalence of cardiovascular disease, when compared with the high-flux treated group.295 A recent multicenter, open, prospective, randomized trial studied over 3 years (MOTheR HDx study) the morbidity and mortality in patients treated with MCO membrane (n=270) and compared the outcomes with online HDF-treated patients (n=282).296 The authors showed a non-inferiority of HDx to online HDF for a composite endpoint of all-cause mortality and cardiovascular events. For all-cause mortality, the incidence rate was 10.7 events per 100 person-years in the expanded HD group compared to 12.2 in the online HDF group - an incidence rate ratio (IRR) of 0.88 (95% CI, 0.60 to 1.27). The confidence interval was fully consistent with comparable survival between expanded HD and online HDF.297 However, formal noninferiority for mortality alone was not established statistically. Another multinational, observational DOPPS study, as an external real-world comparator, compared 597 patients treated MCO membrane versus 1,339 patients treated with online HDF over a median follow-up of 1.6 years. The interim analysis showed, after multivariable adjustment for key demographic, clinical and laboratory variables, the hazard ratio for all-cause mortality of MCO membrane treated group versus online HDF group (HR 0.75, 95% CI 0.54–1.04) remained below the prespecified non-inferiority margin, meeting the criteria for non-inferiority. Results showed no statistically significant differences in all-cause mortality between both modalities.298

Implementation of expanded haemodialysis. Unlike online HDF, which allows measurable treatment optimization via convection-volume targets,162 expanded HD enabled by the MCO dialyzer lacks the optimization of the convective dose. Although MCO therapy offers a practical alternative online HDF,228 it’s wide spread implementation might be limited by its cost. However, different studies showed potential savings could be achieved from this therapy. These include lower doses of medications29,294 and less water and electricity consumption, when compared with online HDF.299–302

Conclusions

Longterm outcomes in conventional HD are still unsatisfactory. Patients are often inflammed, malnourished and anaemic, and their quality of life and rehabilitation are suboptimal. There is a wide spectrum of molecules retained in blood (uremic toxins), and uremia is not fully corrected due to insufficient cleansing. Retention of high level of such molecules, especially the large-size, correlate with specific outcomes. These include inflammation, atherosclerosis, and vascular calcifications, all of which contributes to increased risk of cardiovascular and all-cause mortality. Efficient removal of these molecules requires adequate convection, an essential physiological principle that is deficient in low-flux or inadequate in high-flux HD. Both online HDF and expanded HD enabled by the MCO membrane are empowered by adequate convection and efficient removal of the larger-size uremic toxins. This is in addition to their capability of augmenting the clearance of small-size uremic toxins by diffusion. These safe advanced HD therapies have been shown to improve the quality of life, cardiovascular outcomes, and survival rate in HD patients when compared to conventional HD.

Declarations

Conflict of Interest Statement
The author has no conflicts of interest to declare.
Funding Statement
None.
Acknowledgements
None.

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S): S117–S314. www.kidney-international.org
  2. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2016; http://dx.doi.org/10.1016/S0140-6736(16)32064-5
  3. Kovesdy CP. Epidemiology of chronic kidney disease - an update 2022. Kidney Int. Suppl 2011. 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003.
  4. Mark PB, GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 202 5; 406: 2461–2482. https://doi.org/10.1016/S0140-6736(25)01853-7
  5. Brück K, Stel VS, Gambaro G, et al. on behalf of the European CKD Burden Consortium. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol. 2016; 27: 2135–2147. doi:10.1681/ASN.2015050542
  6. Duff R, Awofala O, Arshad MT, et al. Global health inequalities of chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2024;39. 1692–1709. https://doi.org/10.1093/ndt/gfae048
  7. Johansen KL, Gilbertson DT, Li S, et al. US Renal Data System 2024 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2025;85(6): Suppl 1: A8-A11. doi:10.1053/j.ajkd.2025.02.602
  8. Ortiz A, Lees JS, Torra R, et al. The updated global burden of chronic kidney disease: one death every 20 seconds, Nephrol Dial Transplant. 2026; 0:1-9. https://doi.org/10.1093/ndt/gfag040
  9. Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050. doi: 10.1016/j.kint.2019.07.012
  10. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;3 92(10159):2052–2090. doi: 10.1016/S0140-6736(18)31694-5
  11. Francis, A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7), 473–485. doi: 10.1038/s41581-024-00820-6.
  12. Elsayed ME, Morris AD, Li X, et al. Propensity score matched mortality comparisons of PD and in-centre HD. Nephrol Dial Transplant. 2020;35(12):2172-2182. doi:10.1093/ndt/gfz278.
  13. Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily haemodialysis improves the long-term health-related quality of life. Kidney Int. 2012;82(5):561-569. doi:10.1038/ki.2012.168.
  14. Koh TJK. Nocturnal haemodialysis: improved quality of life and patient outcomes. Int J Nephrol Renovasc Dis. 2019; 12:59–68. doi:10.2147/IJNRD.S165919
  15. Karkar A. Modalities of Haemodialysis: Quality Improvement. Saudi J Kidney Dis Transplant. 2012;23(6):1145-1161. doi:10.4103/1319-2442.103553
  16. Bonthuis M, Kramer A, Bakkaloglu SA, et al. Incidence and prevalence of kidney replacement therapy in Central and Eastern Europe—trends from the ERA Registry. Nephrol Dial Transplant. 2026, 41:1322–1339. https://doi.org/10.1093/ndt/gfaf268
  17. Jha V, Al-Ghamdi SMG, Li G, et al. Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme. Adv Ther. 2023;40(10):4405–4420. doi:10.1007/s12325-023-02608-9
  18. Ng MSN, Chan DNSC, So WKW. Health inequity associated with financial hardship among patients with kidney failure. PLoS One. 2023;18(6):e0287510. doi:10.1371/journal.pone.0287510
  19. Groza C, Groppa L, Rotaru L, et al. Chronic kidney disease – a major public health problem. Mold J Health Sci. 2025;12(2):64-70. https://doi.org/10.52645/MJHS.2025.2.09
  20. Mehrer H, Stolwijk NA. Heroes and Highlights in the History of Diffusion. diffusion-fundamentals.org. 11.2009; 1:1-32. doi:10.62721/diffusion-fundamentals.11.453
  21. Elford WJ. The Principles of Ultrafiltration as Applied in Biological Studies. Proc R Soc B. 1933;112 (778):384–406. https://doi.org/10.1098/rspb.1933.0017
  22. Bolasco P, Altieri P, Andrulli S, et al. Convection versus diffusion in dialysis: an Italian prospective multicentre study. Nephrol Dial Transplant. 2003;18(7): vii50–vii54. doi.org/10.1093/ndt/gfg1080
  23. Hulko M, Haug U, Gauss J, et al. Requirements and Pitfalls of Dialyzer Sieving Coefficients Comparisons. Artif Organs. 2018, 42(12): 1164-1173. doi:10.1111/aor.13278
  24. Ronco C, Clark WR. Haemodialysis membranes. Nature. 2018; 14(6):394-410. https://doi.org/10.1038/s41581-018-0002-x
  25. Santoro A, Mancini E, Basile C, et al. Blood volume controlled haemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney Int. 2002;62(3):1034-1045. doi:10.1046/j.1523-1755.2002.00511.x.
  26. Lameire N, Van Biesen W, Vanholder R. Did 20 years of technological innovations in haemodialysis contribute to better patient outcomes? Clin J Am Soc Nephrol. 2009:4 Suppl 1:S30-S40. doi:10.2215/CJN.04000609
  27. Mitra V, Zaidi S, Mitra S. Pioneering Advances in Haemodialysis: A Review of Contemporary Machines. Semin Dial. 2025;38: 4-11. https://doi.org/10.1111/sdi.13248
  28. Misra M. The basics of haemodialysis equipment. Haemodialysis Int. 2005; 9:30-36. https://doi.org/10.1111/j.1492-7535.2005.01115.x
  29. Lang T, Zawada AM, Theis L, et al. Haemodiafiltration: Technical and Medical Insights. Bioengineering. 2023; 10:145. https://doi.org/10.3390/ bioengineering10020145
  30. Cheung AK. Biocompatibity of haemodialysis Membranes. J Am Soc Nephrol. 1990; 1:150-161. doi:10.1681/ASN.V12150
  31. Davenport A. The changing face of dialyzer membranes and dialyzers. Semin Dial. 2025; 38(1):25-34. doi:10.1111/sdi.13161
  32. Kirsch AH, Lyko R, Nilsson LG, et al. “Performance of Haemodialysis with Novel Medium Cut Off Dialyzers,” Nephrol Dial Transplant. 2017; 32:165–172. doi:10.1093/ndt/gfw310.
  33. Ronco C, Neri M, Lorenzin A, Clark WR. Multidimensional Classification of Dialysis Membranes. Contributions Nephrol. 2017; 191:115-126. doi:10.1159/000479260. In book: Expanded Haemodialysis: Innovative Clinical Approach in Dialysis
  34. Allard B, Begri R, Potier J, Coupel S. Dialyzers biocompatibility and efficiency determinants of sterilization method choice. Le Pharmacien Hospitalier et Clinicien. 2013; 48:e15-e21. http://dx.doi.org/10.1016/j.phclin.2013.01.011
  35. Karkhah S, Pourshaikhian M, Vajargah PG, et al. Needle Direction and Distance of Arteriovenous Fistula Cannulation in Haemodialysis Adequacy; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2023;11(1): e39. doi:10.22037/aaem.v11i1.1943
  36. Ahmed J, Besarab A, Lubkowski T, Frinak S. Effect of differing blood lines on delivered blood flow during haemodialysis. Am J Kidney Dis. 2004;44(3), 498-508. PMID: 15332223
  37. Desai N. Basics of base in haemodialysis solution: Dialysate buffer production, delivery and decontamination. Indian J Nephrol. 2015;25(4):189–193. doi:10.4103/0971-4065.147369
  38. Karkar A, Chaballout A, Haj Ibrahim M, et al. Improving arteriovenous fistula rate: Effect on haemodialysis quality. Haemodialysis Int. 2014; 18:516–521. doi:10.1111/hdi.12102
  39. Stegmayr B, Willems C, Groth T, et al. Arteriovenous access in haemodialysis: A multidisciplinary perspective for future solutions. Int J Artif Organs. 2020;44(1):3–16. doi:10.1177/0391398820922231
  40. Miller LM, Clark LE, Dipchand C, et al. on behalf of the Canadian Society of Nephrology Vascular Access Work Group. Haemodialysis Tunneled Catheter-Related Infections. Can J Kidney Health and Dis. 2016; 3:1-11. doi: 10.1177/2054358116669129
  41. Tong MKH, Wang W, Kwan TH, et al. Water treatment for haemodialysis. Hong Kong J Nephrol. 2001;3(1):7-14.
  42. Ismail N, Becker BN, Hakim RM. Water treatment for haemodialysis. Am J Nephrol. 1996;16(1):60-72. doi:10.1159/000168972.
  43. Layman-Amato R, Curtis J, Payne GM. Water Treatment for Haemodialysis: An Update. Nephrol Nursing J. 2013;40(5):383-404. 465 Quiz 405. https://pubmed.ncbi.nlm.nih.gov/24308107/
  44. Payne GM, Curtis J. Water Treatment for Haemodialysis: Keeping Patients Safe. Nephrol Nursing J. 2021;48(4):315-345. doi:10.37526/1526-744X.2021.48.4.315
  45. Ward RA. Ultrapure dialysate. Semin Dial. 2004;17(6):489-497. doi:10.1111/j.0894-0959.2004.17617.x.
  46. Canaud B, Lertdumrongluk P. Ultrapure Dialysis Fluid: A New Standard for Contemporary Haemodialysis. Nephro Urol Mon. 2012;4(3):519–523. doi:10.5812/numonthly.3060
  47. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of haemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int. 2006;69: 1229–1236. doi:10.1038/sj.ki.5000188
  48. Brunelli SM, Chertow GM, Ankers ED, et al. Shorter dialysis times are associated with higher mortality among incident haemodialysis patients. Kidney Int. 2010;77(7):630-636. doi:10.1038/ki.2009.523
  49. Denhaerynck K, Manhaeve D, Dobbels F, et al. Prevalence and consequences of nonadherence to haemodialysis regimens. Am J Crit Care. 2007;16(3): 222-235. quiz 236. PMID:17460313
  50. Locatelli F, Buoncristiani U, Canaud B, et al. Dialysis dose and frequency. Nephrol Dial Transplant. 2005; 20:285-296. doi:10.1093/ndt/gfh550
  51. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily haemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive haemodialysis patients. Am J Kidney Dis. 2001;38: 371-376. doi:10.1053/ajkd.2001.26103
  52. Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: Survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant. 2008;23: 3283-3289. doi:10.1093/ndt/gfn210
  53. The FHN Trial Group. In-center haemodialysis six times per week versus three times per week. N Engl J Med. 2010;363: 2287-2300. doi:10.1056/NEJMoa1001593
  54. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in haemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int. 2006;69: 1222-1228. doi:10.1038/sj.ki.5000186
  55. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of Frequent Nocturnal Haemodialysis vs Conventional Haemodialysis on Left Ventricular Mass and Quality of Life: A Randomized Controlled Trial. JAMA. 2007; 298:1291-1299. doi:10.1001/jama.298.11.1291
  56. Rocco MV, Lockridge RS Jr, Beck GJ, et al. The effects of frequent nocturnal home haemodialysis: The Frequent Haemodialysis Network Nocturnal Trial. Kidney Int. 2011; 80:1080-1091. doi:10.1038/ki.2011.213
  57. Rao M, Muirhead N, Klarenbach S, et al. Management of anaemia with quotidian haemodialysis. Am J Kidney Dis. 2003;42:S18-23. doi:10.1016/s0272-6386(03)00533-x
  58. David S, Kumpers P, Eisenbach GM, et al. Prospective evaluation of an in-centre conversion from conventional hemodialysis to an intensified nocturnal strategy. Nephrol Dial Transplant. 2009;24: 2232-2240. doi:10.1093/ndt/gfp029
  59. Ayus JC, Achinger SG, Mizani MR, et al. Phosphorus balance and mineral metabolism with 3 h daily haemodialysis. Kidney Int. 2007;71: 336-342. doi:10.1038/sj.ki.5002044
  60. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting “daily” haemodialysis. Kidney Int. 1999; 55:2467-2476. doi:10.1046/j.1523-1755.1999.00493.x
  61. Galland R, Traeger J, Arkouche W, et al. Short daily haemodialysis rapidly improves nutritional status in haemodialysis patients. Kidney Int. 2001; 60:1555-1560. doi:10.1046/j.1523-1755.2001.00959.x
  62. Mowatt G, Vale L, MacLeod A. Systematic review of the effectiveness of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Int J Technol Assess Health Care. 2004;20(3):258-268. doi:10.1017/s0266462304001060
  63. Pauly RP, Gill JS, Rose CL, et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant. 2009;24: 2915-2919. doi:10.1093/ndt/gfp295
  64. Agar JW, Knight RJ, Simmonds RE, et al. Haemodialysis: An Australian cost comparison with conventional satellite haemodialysis. Nephrol. 2005; 10:557-570. doi:10.1111/j.1440-1797.2005.00471.x
  65. Komenda P, Gavaghan MB, Garfield SS, et al. An economic model for incenter, conventional home, and more frequent home haemodialysis. Kidney Int. 2012; 81:307-313. doi:10.1038/ki.2011.338
  66. Oshvandi K, Kavyannejad R, Borzuo SR, Gholyaf M. High-Flux and Low-Flux Membranes: Efficacy in Haemodialysis. Nurs Midwifery Stud. 2014;3(3): e21764. doi:10.17795/nmsjournal21764
  67. Zweigart C, Boschetti-de-Fierro A, Hulko M, et al. Medium cut-off membranes – closer to the natural kidney removal function. Int J Artif Organs. 2017;40(7):328-334. doi:10.5301/ijao.5000603
  68. Storr M, Ward RA. Membrane innovation: closer to native kidneys. Nephrol Dial Transplant. 2018; 33: iii22–iii27. doi:10.1093/ndt/gfy228
  69. Gondouin B, Hutchison CA. High cut-off dialysis membranes: current uses and future potential. Adv Chronic Kidney Dis. 2011;18(3):180-187. doi:10.1053/j.ackd.2011.02.006.
  70. Laville M, Dorval M, Ros JF, et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 2014; 86(6):1260-1267. doi:10.1038/ki.2014.225
  71. Kessler M, Gangemi C, Martones AG, et al. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular haemodialysis patients: a prospective proof-of-concept study. Haemodialysis Int. 2013;17(2):282-293. doi:10.1111/j.1542-4758.2012.00733.x
  72. Meijers B, Metalidis B, Vanhove T, et al. A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. Nephrol Dial Transplant. 2017; 32: 707–714. doi:10.1093/ndt/gfw461
  73. Zhang Y, Gao W, Li X. Vitamin E-coated dialyzer alleviates erythrocyte deformability dysfunction in patients with end-stage renal disease undergoing haemodialysis. Exp Ther Med. 2022;24(1):480. doi:10.3892/etm.2022.11407
  74. Hassell DR, van der Sande FM, Kooman JP, et al. Optimizing dialysis dose by increasing blood flow rate in patients with reduced vascular-access flow rate. Am J Kidney Dis. 2001;38(5):948-955. doi:10.1053/ajkd.2001.28580
  75. Rafik H, Aatif T, Azizi M, et al. The Impact of Blood Flow Rate on Dialysis Dose and Phosphate Removal. Nephrol Dial Transpl 2017; 32, iii624-iii625. doi:10.1093/ndt/gfx175.MP534
  76. Mavromatidis KS, Kriki PA, Impis ES, et al. Effect of Blood Supply to the Filter on the Clearance of Small Molecular Weight Toxins during Conventional Haemodialysis. J Biosciences Med. 2025;13(9): 449-460. doi:10.4236/jbm.2025.13903
  77. Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the haemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999; 10(3): 601–609. doi:10.1681/ASN.V103601
  78. Raj DSC, Ouwendyk M, Francoeur R, Pierratos A. Beta (2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant. 2000; 15(1): 58–64. doi:10.1093/ndt/15.1.58
  79. Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly haemodialysis. Am J Kidney Dis. 2002; 40(6): 1211–1218. doi:10.1053/ajkd.2002.36883
  80. Schneditz D, Ronco C, Levin N. RENAL RESEARCH INSTITUTE SYMPOSIUM: Temperature Control by the Blood Temperature Monitor. Semin Dial. 2003; 16: 477-482. https://doi.org/10.1046/j.1525-139X.2003.16103.x
  81. Pérgola PE, Habiba NM, Johnson JM. Body temperature regulation during haemodialysis in long-term patients: is it time to change dialysate temperature prescription? Am J Kidney Dis. 2004;44(1):155-165. doi:10.1053/j.ajkd.2004.03.036.
  82. Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol. 2006;1(6): 1216–1225. doi:10.2215/CJN.02010606
  83. Selby NM, Lambie SH, Camici PG, et al. Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis. 2006;47(5): 830–841. doi:10.1053/j.ajkd.2006.01.012
  84. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007;2(1):89-99. doi:10.2215/CJN.01170905
  85. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and Non cardiovascular Mortality Among Patients Starting Dialysis. JAMA. 2009;302;(16):1782 1789. doi:10.1001/jama.2009.1488
  86. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid Retention Is Associated with Cardiovascular Mortality in Patients Undergoing Long-Term Haemodialysis. Circulation. 2009;119(5): 671–679. https://doi.org/10.1161/CIRCULATIONAHA.108.807362
  87. Zoccali C, Tripepi G, Carioni P, et al. Fluid overload trajectories and mortality in haemodialysis patients. J Intern Med. 2025;297(2):201-212. doi:10.1111/joim.20049
  88. McIntyre CW, Burton JO, Selby NM, et al. Haemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow. Clin J Am Soc Nephrol. 2008;3(1):19–26. doi:10.2215/CJN.03170707
  89. Chou JA, Kalantar-Zadeh K. Volume Balance and Intradialytic Ultrafiltration Rate in the Haemodialysis Patient. Curr Heart Fail Rep. 2017 Oct;14(5):421–427. doi:10.1007/s11897-017-0356-6
  90. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality Kidney Int. 2011;79(2):250-257. doi:10.1038/ki.2010.383
  91. Engelen MM, Verhamme P, Vanassche T. Clotting of the Extracorporeal Circuit in Haemodialysis: Beyond Contact-Activated Coagulation. Semin Nephrol. 2023;43(6):151473. doi:10.1016/j
  92. Claudel SE, Miles LA, Murea M. Anticoagulation in haemodialysis: A narrative review. Semin Dial. 2021;34(2):103-115. doi:10.1111/sdi.12932
  93. May J, Cuker A. Practical guide to the diagnosis and management of heparin-induced thrombocytopenia. Hematology. 2024;2024(1):388-395. https://doi.org/10.1182/hematology.2024000566
  94. Davenport A. Low-molecular-weight heparin for routine haemodialysis. Haemodialysis Int. 2008;12 (Suppl 2): S34-S37. doi:10.1111/j.1542-4758.2008.00322.x
  95. Rodger MA, Ramsay T, MacKinnon M, et al. Tinzaparin Versus Dalteparin for Periprocedure Prophylaxis of Thromboembolic Events in Haemodialysis Patients: A Randomized Trial. Am J Kidney Dis. 2012;60(3): 427-434. doi:10.1053/j.ajkd.2012.01.020.
  96. Zhang Y, Guo S, Xu J. Multifunctional applications and research advances of low-molecular-weight heparin. Front Pharmacol. 2025;16: https://doi.org/10.3389/fphar.2025.1585762
  97. Shen JI, Winkelmayer WC. Use and Safety of Unfractionated Heparin for Anticoagulation During Maintenance Haemodialysis. Am J Kidney Dis. 2012;60(3):473-486. doi:10.1053/j.ajkd.2012.03.017
  98. Oh HS, Kim T, Gu DH, et al. Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis. Molecules. 2022;27(6), 1881; https://doi.org/10.3390/molecules27061881
  99. Lin Y, Shao Y, Liu Y, et al. Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis. Ren Fail. 2022;44(1):1263-1279. doi:10.1080/0886022X.2022.2105233
  100. Liu C, Yang Y, Ren J, et al. Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis. Crit Care. 2025;30(1):43.doi:10.1186/s13054-025-05813-w
  101. Mikaelsson M.E. (1991) The Role of Calcium in Coagulation and Anticoagulation. In: Sibinga C.T.S., Das P.C., Mannucci P.M. (eds) Coagulation and Blood Transfusion. Developments in Hematology and Immunology, vol 26. Springer, Boston, MA
  102. Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost. 2007; 5(10): 2055–2061. doi:10.1111/j.15387836.2007.02710
  103. Aniort J, Richard F, Thouy F, et al. Deciphering simplified regional anticoagulation with citrate in intermittent haemodialysis: a clinical and computational study. Scientific Reports. 2024; 14:19778. https://doi.org/10.1038/s41598-024-70708-9
  104. Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant. 2006;21: 444–449. doi:10.1093/ndt/gfi203
  105. Zimbudzi E. Intermittent saline flushes or continuous saline infusion: what works better when heparin-free dialysis is recommended? Int J Nephrol Renovasc Dis. 2013; 6:65–69. doi:10.2147/IJNRD.S43252
  106. Vega-Alava, KM, Andres, S. Continuous infusion versus intermittent saline flushing in preventing clot formation during heparin-free haemodialysis. Kidney Int Reports. 2019;4(7), S355. https://doi.org/10.1016/j.ekir.2019.05.914
  107. Cheng Y-L, Yu A W, Tsang K-Y, et al. Anticoagulation during haemodialysis using a citrate-enriched dialysate: a feasibility study. Nephrol Dial Transplant. 2011;26(2):641–646. doi:10.1093/ndt/gfq396
  108. Grundström G, Christensson A, Alquist M, et al. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol. 2013; 14:216. doi:10.1186/1471-2369-14-216
  109. Sands JJ, Kotanko P, Segal JH, et al. Effects of citrate acid concentrate (citrasate®) on heparin N requirements and haemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012;33(1-3):199-204. doi:10.1159/000334157
  110. Leung KCW, Tai DJ, Ravani P, et al. Citrate vs. acetate dialysate on intradialytic heparin dose: A double blind randomized crossover study. Haemodialysis Int. 2016; 20:537-547. https://doi.org/10.1111/hdi.12433
  111. Gabutti L, Lucchini B, Marone C, et al. Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol. 2009; 10:7. doi:10.1186/1471-2369-10-7
  112. Richtrova P, Rulcova K, Mares J, Reischig T. Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs. 2011 Jan;35(1):83-88. doi:10.1111/j.1525-1594.2010.01038.x
  113. Singer RF, Williams O, Mercado C, et al. Regional citrate anticoagulation in haemodialysis: an observational study of safety, efficacy, and effect on calcium balance during routine care. Can J Kidney Health Dis. 2016;3: 22. doi:10.1186/s40697-016-0113-x
  114. Peng B, Lu J, Guo H, et al. Regional citrate anticoagulation for replacement therapy in patients with liver failure: A systematic review and meta-analysis. Front Nutr. 2023; 10:2023. https://doi.org/10.3389/fnut.2023.1031796
  115. Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the World’s First High Permeability Membrane. Contributions to Nephrol. 2011; 173:119-129. doi:10.1159/000328961
  116. Boer WH, Liem Y, de Beus E, Abrahams AC. Acute reactions to polysulfone/polyethersulfone dialysers: literature review and management. Neth J Med. 2017 Jan;75(1):4-13. https://pubmed.ncbi.nlm.nih.gov/28124665/
  117. Cheng C, Sun S, Zhao C. Progress in heparin and heparin-like/mimicking polymer functionalized biomedical membranes. J Mater Chem. 2014; 2 (44): 7649-7672. https://doi.org/10.1039/c4tb01390e
  118. Xiong Z, Liu F, Lin H, et al. Covalent Bonding of Heparin on the Crystallized Poly (lactic acid) (PLA) Membrane to Improve Hemocompability via Surface Cross-Linking and Glycidyl Ether Reaction. ACS Biomater Sci Eng. 2016;2(12): 2207-2216. https://doi.org/10.1021/acsbiomaterials.6b00413
  119. Chanard J, Lavaud S, Paris B, et al. Assessment of heparin binding to the AN69 ST haemodialysis membrane: I. Preclinical studies. ASAIO J. 2005;51(4):342-347. doi:10.1097/01.mat.0000169119.06419.ed.
  120. Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST haemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J. 2005 Jul-Aug;51(4):348-351. doi:10.1097/01.mat.0000169121.09075.53
  121. Gois PHF, McIntyre D, Ratanjee S, et al. Haemodialysis without Systemic Anticoagulation: A Randomized Controlled Trial to Evaluate Five Strategies in Patients at a High Risk of Bleeding. Med Sci. 2024;12(3), 38; https://doi.org/10.3390/medsci12030038
  122. Guéry B, Alberti C, Servais A, et al. Haemodialysis without Systemic Anticoagulation: A Prospective Randomized Trial to Evaluate 3 Strategies in Patients at Risk of Bleeding. PLoS ONE. 2014;9(5): e97187. https://doi.org/10.1371/journal.pone.0097187
  123. Yang SK, Xiao L, Xu B, et al. Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in haemodialysis patients: a systematic review and meta-analysis. Ren Fail. 2014;36(5):722-731. doi:10.3109/0886022X.2014.890858
  124. Islam MS, Hassan ZA, Chalmin F, et al. Vitamin E–Coated and Heparin-Coated Dialyzer Membranes for Heparin-Free Haemodialysis: A Multicenter, Randomized, Crossover Trial. Am J Kidney Dis. 2016; 68(5), 752-762. doi:10.1053/j.ajkd.2016.05.013. Epub 2016 Jun 23
  125. Vandenbosch I, Dejongh S, Claes K, et al. Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study, Clin Kidney J. 2021;14(8):1901–1907. https://doi.org/10.1093/ckj/sfaa228
  126. Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr. 2016;39(1):21–24. doi:10.18773/austprescr.2016.008
  127. Roberts DM, Sevastos J, Carland JE, et al. Clinical Pharmacokinetics in Kidney Disease. Clin J Am Soc Nephrol. 2018;13(8):1254–1263. doi:10.2215/CJN.05150418
  128. Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int. 1999; 56, Suppl. 72:S-24–S-28. https://doi.org/10.1046/j.1523-1755.56.s.72.2.x
  129. Nagano H, Tomori K, Koiwa M, et al. Identification of Prescribing Patterns in Haemodialysis Outpatients Taking Multiple Medications. Pharmacy. 2023; 11(2), 43; https://doi.org/10.3390/pharmacy11020043
  130. Sudha MJ, Salam HS, Viveka S, Udupa AL. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance haemodialysis. J Nat Sci Biol Med. 2017;8(1):64–68. doi:10.4103/0976-9668.198348
  131. Tieu A, Leither M, Urquhart BL, Weir MA. Clearance of cardiovascular medications during haemodialysis. Curr Opin Nephrol Hypertens. 2016;25(3):257-267. doi:10.1097/MNH.0000000000000216
  132. Chen YK, Chu CS, Niu SW, et al. The prognostic value of URR equals that of Kt/V for all ‑cause mortality in Taiwan after 10 ‑year follow ‑up. Scientific Reports. 2023;13: 8923. https://doi.org/10.1038/s41598-023-35353-8
  133. Spalding EM, Chandna SM, Davenport A, Farrington K. Kt/V underestimates the haemodialysis dose in women and small men. Kidney Int. 2008;74(3):348-355. doi:10.1038/ki.2008.185
  134. Mammen C, Goldstein SL, Milner R, White CT. Standard Kt/V thresholds to accurately predict single-pool Kt/V targets for children receiving thrice-weekly maintenance haemodialysis. Nephrol Dial Transplant. 2010;25(9):3044-3050. doi:10.1093/ndt/gfq165
  135. Daugirdas JT, Depner TA, Gotch FA, et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int. 1997;52(5):1395-1405. doi:10.1038/ki.1997.467
  136. Hauk M, Kuhlmann MK, Riegel W, Köhler H. In vivo effects of dialysate flow rate on Kt/V in maintenance haemodialysis patients. Am J Kidney Dis. 2000;35(1):105-111. doi:10.1016/S0272-6386(00)70308-8
  137. Vanholder R, Baurmeister U, Brunet P, et al. for the European Uremic Toxin Work Group. A Bench to Bedside View of Uremic Toxins. J Am Soc Nephrol. 2008;19: 863–870. doi:10.1681/ASN.2007121377
  138. Wolley MJ, Hutchison CA. Large uremic toxins an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant. 2018; 33(suppl 3): iii6-iii11. doi: 10.1093/ndt/gfy179
  139. Collins AJ, Robert, Foley RN, et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011;57(1): Suppl 1. (January), A8. doi:10.1053/j.ajkd.2010.10.007. U.S. Renal Data System, the data supplied by the United States Renal Data System (USRDS): 2010 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. http://www.usrds.org/faq.htm
  140. Pippias M, Kramer A, Noordzij M, et al. The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary, Clin Kidney J. 2017;10(2):154–169. https://doi.org/10.1093/ckj/sfw135
  141. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and non-cardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782-1789. doi:10.1001/jama.2009.1488
  142. Kramer A, Stel V, Zoccali C, et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant. 2009;24:3557-3566. doi:10.1093/ndt/gfp519
  143. Ashuntantang G, Osafo C, Olowu WA, et al. Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: a systematic review. Lancet Glob Health. 2017;5(4): e408-e417. doi:10.1016/S2214-109X(17)30057-8
  144. European Uremic Toxin (EUTOX) database Website. Available at: https://database.uremic-toxins.org/soluteList.php. Accessed on 12 September 2026. https://database.uremic-toxins.org/home.php
  145. Chmielewski M, Cohen G, Wiecek A, Carrero JJ. The Peptidic Middle Molecules: Is Molecular Weight Doing the Trick? Semin Nephrol. 2014;34(2):118-134. https://doi.org/10.1016/j.semnephrol.2014.02.005
  146. Wolley M, Jardine M, Hutchison CA. Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. Clin J Am Soc Nephrol. 2018;13(5):805-814. doi:10.2215/CJN.10110917
  147. Rosner MH, Reis T, Husain-Syed F, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021;16(12):1918-1928. doi:10.2215/CJN.02660221
  148. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006;17(2):546-555. doi:10.1681/ASN.2005020132
  149. Liabeuf S, Lenglet A, Desjardins L, et al. European Uremic Toxin Work Group (EUTox). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82(12):1297-1303. doi:10.1038/ki.2012.301
  150. Wungu CDK, Susilo H, Alsagaff MY, et al. Role of klotho and fibroblast growth factor 23 in arterial calcification, thickness, and stiffness: a meta-analysis of observational studies. Scientific Reports. 2024;14:5712. https://doi.org/10.1038/s41598-024-56377-8
  151. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545-2552. doi:10.1161/CIRCULATIONAHA.108.844506
  152. Vetrano D, De Pascalis A, Tomassetti A, et al. Fibroblast growth factor 23 and mortality, heart failure and cardiovascular events across the chronic kidney disease spectrum - A systematic review and meta-analysis. Europ Int Med. 2026;106987. https://doi.org/10.1016/j.ejim.2026.106987
  153. Sakurai K, Saito T, Yamauchi F, Hosoya H. “Is On ‑Line HDF the Best Strategy for Restless Legs Syndrome in Dialysis Patients? ” Nephrol Dial Transplant. 2013;28: 425. Poster, 50th ERA EDTA Congress (Istanbul, 2013).
  154. Sakurai K, Kurihara Y, Hosoya H, et al. Treatment of Restless Legs Syndrome in Dialysis Patients. Semin Dial. 2026;39(4):207-209. doi:10.1111/sdi.70040
  155. Zhu L, Gan L, Xu Y, et al. Performance-based classification of dialyzers: integrating YKL-40 for advanced middle-molecule clearance - A Chinese expert consensus. Ren Fail. 2026;48(1):2658983. doi:10.1080/0886022X.2026.2658983
  156. Cohen G, Haag-Weber M, Mai B, et al. Effect of immunoglobulin light chains from haemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol. 1995;6(6):1592-1599. doi:10.1681/ASN.V661592
  157. Desjardins L, Liabeuf S, Lenglet A, et al. European Uremic Toxin (EUTox) Work Group. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel). 2013; 8;5(11):2058-2073. doi:10.3390/toxins5112058
  158. Wu PH, Lin YT, Chiu YW, et al. The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in haemodialysis patients. Sci Rep. 2021;15;11(1):3786. doi:10.1038/s41598-021-83383-x
  159. Suhendra A, Ramadani S, Tarigan RR. Association Between Indoxyl Sulfate Levels and Major Cardiovascular Events in Haemodialysis Patients with Chronic Kidney Disease. J Society Medicine. 2025;4(10):312-319. https://doi.org/10.71197/jsocmed.v4i10.259
  160. Leypoldt, JK. Solute fluxes in different treatment modalities. Nephrol Dial Transplant. 2000;15 Suppl 1:3-9. doi:10.1093/oxfordjournals.ndt.a027961.
  161. Ledebo I, Blankestijn PJ. Haemodiafiltration-optimal efficiency and safety. Nephrol Dial Transplant Plus. 2010;3(1):8-16. doi:10.1093/ndtplus/sfp149
  162. Bergling K, Blankestijn PJ. Beyond Diffusion: Clinical Perspectives on Online Haemodiafiltration and Medium Cut-Off Dialyzers. Am J Kidney Dis. 2026;8(2):315-322. doi:10.1053/j.ajkd.2025.11.018
  163. Friedrich JO, Wald R, Bagshaw SM, et al. Haemofiltration compared to haemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care. 2012;16(4): R146. doi:10.1186/cc11458.
  164. Karkar A. CRRT Book. Editor: Ayman Karkar. INTECH CRRT Book. 2019. http://dx.doi.org/10.5772/intechopen.82503
  165. Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize Therapy. Ann Intensive Care. 2020; 10:32. https://doi.org/10.1186/s13613-020-0648-y
  166. Karkar A. Advances in haemodiafiltration. Editor: Ayman Karkar. INTECH Haemodiafiltration Book. ISBN 978-953-51-2562-2564, September 2016.
  167. Lang T, Zawada AM, Theis L, et al. Haemodiafiltration: Technical and Medical Insights. Bioengineering (Basel). 2023;10(2):145. doi:10.3390/bioengineering10020145.
  168. Canauda B, Cheninea L, Henrieta D, Leraya H. Online Haemodiafiltration: A Multipurpose Therapy for Improving Quality of Renal Replacement Therapy. Ronco C, Cruz DN (eds): Haemodialysis – From Basic Research to Clinical Trials. Contrib Nephrol. 2008; 161:191–198. doi:10.1159/000130677
  169. Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant. 2009;24(2):562-570. doi:10.1093/ndt/gfn522.
  170. Karkar A, Abdelrahman M, Locatelli F. A Randomized Trial on Health-Related Patient Satisfaction Level with High-Efficiency Online Haemodiafiltration versus High-Flux. Blood Purif. 2015; 40:84–91. doi:10.1159/000381255
  171. Tattersall J, Ward RA, Canaud B, Ward R. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant. 2013;28(3):542-550. doi:10.1093/ndt/gfs530
  172. Pacitti A. The concept of ultrapure solution online production. G Ital Nefrol. 2008; 25(Suppl 41): S28–S32. PMID:18473318
  173. Penne EL, Visser L, van den Dorpel MA, et al. Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online haemodiafiltration in routine clinical practice. Kidney Int. 2009;76(6):665-672. doi:10.1038/ki.2009.245. Epub 2009 Jul 15.
  174. Ficociello LH, Busink E, Sawin D-A, Winter A. Global real-world data on haemodiafiltration: An opportunity to complement clinical trial evidence. Semin Dial. 2022; 35(5): 440-445. doi:10.1111/sdi.13085
  175. Canaud B, Köhler K, Sichart JM, Möller S. Global prevalent use, trends and practices in haemodiafiltration. Nephro Dial Transplant. 2020;35(3):398-407. https://doi.org/10.1093/ndt/gfz005
  176. Battaglia Y, Shroff R, Meijers B, et al. Haemodiafiltration versus high-flux haemodialysis - a Consensus Statement from the EuDial Working Group of the ERA. Nephrol Dial Transplant. 2025;40(8):1590-1614. doi:10.1093/ndt/gfaf024
  177. Cromm K, Pham N, Yuen T, et al. on behalf of the CONVINCE Scientific Committee and Investigators. Characteristics of Populations Included in Randomized Controlled Trials of Haemodiafiltration and Registry Real-Life Populations. C J Am Soc Nephrol. 2026;21(1):95-107. https://doi.org/10.2215/CJN.0000000855
  178. Canaud B, Barbieri C, Marcelli D, et al. Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online haemodiafiltration. Kidney Int. 2015;88(5):1108-1116. doi: 10.1038/ki.2015.139
  179. Peters SAE, Bots ML, Canaud B, et al. HDF Pooling Project Investigators. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant. 2016;31(6):978-984. doi:10.1093/ndt/gfv349.
  180. Cerdá J, Ronco C. Modalities of continuous renal replacement therapy: technical and clinical considerations. Semin Dial. 2009;22(2):114-122. doi:10.1111/j.1525-139X.2008.00549.x.
  181. Stenvinkel P, Alvestrand A. Review Articles: Inflammation in End-stage Renal Disease: Sources, Consequences, and Therapy. Semin Dial. 2002;15: 329-337. https://doi.org/10.1046/j.1525-139X.2002.00083.x
  182. Carrero JJ, Chmielewski M, Axelsson J, et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr. 2008;27(4):557-564. doi: 10.1016/j.clnu.2008.04.007
  183. Dheda S, Vesey DA, Hawley C, et al. Effect of a Haemodialysis Session on Markers of Inflammation and Endotoxin. Int J Inflam. 2022; 2022:8632245. doi: 10.1155/2022/8632245
  184. Stuard S, Hugh-Jones C, Chatoth D, et al. Uremic Toxins and Haemodiafiltration: From Molecular Mechanisms to Clinical Outcomes. Toxins (Basel). 2026; 18(7):312. doi:10.3390/toxins18070312
  185. Canaud B, Bosc JY, Leray-Moragues H, et al. On-line haemodiafiltration. Safety and efficacy in long-term clinical practice. Nephrol Dial Transplant. 2000;15(Suppl 1): 60–67. doi:10.1093/oxfordjournals.ndt.a027966
  186. den Hoedt CH, Bots ML, Grooteman MPC, et al. for the CONTRAST Investigators. Online haemodiafiltration reduces systemic inflammation compared to low-flux Haemodialysis. Kidney Int. 2014; 86(2):423–432. doi.org/10.1038/ki.2014.9, hdl.handle.net/1765/68509
  187. Vaslaki LR, Berta K, Major L, et al. On-line Haemodiafiltration Does Not Induce Inflammatory Response in End-stage Renal Disease Patients: Results from a Multicenter Cross-over Study. Artificial Organs. 2005;29: 406-412. https://doi.org/10.1111/j.1525-1594.2005.29068.x
  188. Panichi V, Manca-Rizza G, Paoletti S, et al. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial. Nephrol Dial Transplant. 2006; 21(3):756–762. doi:10.1093/ndt/gfi189
  189. Panichi V, Manca-Rizza G, Paoletti S, et al. on behalf of the RISCAVID Study Group. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008; 23: 2337–2343. doi:10.1093/ndt/gfm951
  190. Vilar E, Fry AC, Wellsted D, et al. Long-term outcomes in online haemodiafiltration and high-flux haemodialysis: a comparative analysis. Clin J Am Soc Nephrol. 2009; 4: 1944–1953. doi:10.2215/CJN.05560809
  191. Filiopoulos V, Hadjiyannakos D, Metaxaki P, et al. Inflammation and oxidative stress in patients on haemodiafiltration. Am J Nephrol. 2008;28(6):949-957. doi:10.1159/000142724
  192. Ağbaş A, Canpolat N, Çal ışkan S, et al. Haemodiafiltration is associated with reduced inflammation, oxidative stress and improved endothelial risk profile compared to high-flux haemodialysis in children. PLoS ONE. 2018;13(6): e0198320. https://doi.org/10.1371/journal.pone.0198320
  193. Locatelli F, Altieri P, Andrulli S, et al. Haemofiltration and haemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol. 2010;21(10): 1798-1807. doi:10.1681/ASN.2010030280
  194. Canaud B, Blankestijn PJ, Grooteman MPC, Davenport A. Why and how high volume haemodiafiltration may reduce cardiovascular mortality in stage 5 chronic kidney disease dialysis patients? A comprehensive literature review on mechanisms involved. Semin Dial. 2022;35(2):117-128. doi:10.1111/sdi.13039
  195. Blankestijn PJ, Vernooij RWM, Hockham C, et al. for the CONVINCE Scientific Committee Investigators. Effect of Haemodiafiltration or Haemodialysis on Mortality in Kidney Failure. N Engl J Med. 2023;389(8):700-709. doi:10.1056/NEJMoa2304820
  196. Lin CL, Huang CC, Chang CT, et al. Clinical improvement by increased frequency of on-line hemodialfiltration. Ren Fail. 2001; 23: 193–206. doi:10.1081/jdi-100103491
  197. Schiffl H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res. 2007; 12(1): 26–33. PMID:17363355
  198. Kantartzi K, Panagoutsos S, Mourvati E, et al. Can dialysis modality influence quality of life in chronic haemodialysis patients? Low-flux haemodialysis versus high-flux haemodiafiltration: a cross-over study. Ren Fail. 2013;35(2):216-221. doi:10.3109/0886022X.2012.743858
  199. Ethier I, Nevis I, Suri RS. Quality of Life and Haemodynamic Effects of Switching from Haemodialysis to Haemodiafiltration: A Canadian Controlled Cohort Study. Canadian Kidney Health Dis. 2021;8. doi:10.1177/20543581211057717
  200. Rose M, Fischer F, Liegl G, et al. The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with haemodiafiltration. Kidney Int. 2024; 106, 961-971. doi:10.1016/j.kint.2024.07.014
  201. Maduell F, Navarro V, Rius A, et al. Improvement of nutritional status in patients with short daily on-line haemodiafiltration]. Nefrologia. 2004;24(1):60-66. PMID: 15083959
  202. Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line haemodiafiltration and high-flux haemodialysis: a prospective clinical study. J Am Soc Nephrol. 2000;11(12):2344-2350. doi:10.1681/ASN.V11122344.
  203. Mazairac AHA, Ardine de Wit G, Grooteman MPC, et al. Effect of Haemodiafiltration on Quality of Life over Time. Clin J Am Soc Nephrol. 2013;8(1):82-89. doi:10.2215/CJN.00010112
  204. Bossola M, Mariani I, Antocicco M, et al. Effect of online haemodiafiltration on quality of life, fatigue and recovery time: a systematic review and meta ‑analysis. J Artificial Organs. 2025;28(1):15–24. doi:10.1007/s10047-024-01459-7
  205. Vernooij RWM, Hockham C, Strippoli GFM, et al. on behalf of the CONVINCE Scientific Committee and the HDF Pooling Project Investigators. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2024;404(10464):1742-1749. doi:10.1016/S0140-6736(24)01859-2
  206. Grooteman MPC, van den Dorpel MA, Bots ML, et al. for the CONTRAST Investigators. Effect of Online Haemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes. J Am Soc Nephrol. 2012;23(6):1087–1096. doi:10.1681/ASN.2011121140
  207. Ok E, Asci G, Toz H, et al. On behalf of the ‘Turkish Online Haemodiafiltration Study’. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transpl. 2013;28(1):192–202. https://doi.org/10.1093/ndt/gfs407
  208. Maduell F, Moreso F, Pons M, et al. ESHOL Study Group. High-efficiency postdilution online haemodiafiltration reduces all-cause mortality in haemodialysis patients. J Am Soc Nephrol. 2013;24(3):487-497. doi:10.1681/ASN.2012080875
  209. Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving haemodiafiltration versus haemodialysis: European results from the DOPPS. Kidney Int. 2006;69(11):2087-2093. doi:10.1038/sj.ki.5000447
  210. Davenport A, Peters SAE, Bots ML, et al. HDF Pooling Project Investigators. Higher convection volume exchange with online haemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size. Kidney Int. 2016;89(1):193-199. doi:10.1038/ki.2015.264
  211. Nistor I, Palmer SC, Craig JC, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev. 2015;2015(5):CD006258. doi:10.1002/14651858.CD006258.pub2.
  212. Locatelli F, Karaboyas A, Pisoni RL, et al. Mortality risk in patients on haemodiafiltration versus haemodialysis: a 'real-world' comparison from the DOPPS. Nephrol Dial Transplant. 2018;33(4):683-689. doi:10.1093/ndt/gfx277.
  213. Strogoff-de-Matos JP, Canziani MEF, Barra ABL. Mortality on Haemodiafiltration Compared to High-Flux Haemodialysis: A Brazilian Cohort Study. Am J Kidney Dis. 2025;86(3):335-342. doi:10.1053/j.ajkd.2025.04.013
  214. Strippoli GFM, Tripepi G, Canaud Bet al. Haemodiafiltration versus High-flux Haemodialysis and Risk of Mortality. A Multinational Target Trial Emulation. J Am Soc Nephrol. 2026;13. doi:10.1681/ASN.0000001225
  215. AlSahow A, Muenz D, Al-Ghonaim MA, et al. Kt/V: achievement, predictors and relationship to mortality in haemodialysis patients in the Gulf Cooperation Council countries: results from DOPPS (2012-18). Clin Kidney J. 2020;14(3):820-830. doi:10.1093/ckj/sfz195
  216. Morena M, Jaussent A, Chalabi L, et al. FRENCHIE Study Investigators. Treatment tolerance and patient-reported outcomes favor online haemodiafiltration compared to high-flux haemodialysis in the elderly. Kidney Int. 2017;91(6):1495-1509. doi:10.1016/j.kint.2017.01.013
  217. Mazairac AHA, Blankestijn PJ, Grooteman MPC, et al. On behalf of the CONTRAST. The cost–utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial Transplant. (2013) 28: 1865–1873. doi:10.1093/ndt/gft045
  218. Ramponi F, Ronco C, Mason G, et al. Cost-effectiveness analysis of online haemodiafiltration versus high-flux haemodialysis. Clinicoecon Outcomes Res. 2016:8:531-540. doi:10.2147/CEOR.S109649
  219. Schouten AEM, Fischer F, Blankestijn PJ, et al. CONVINCE Scientific Committee. A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online haemodiafiltration compared to high-flux haemodialysis. Kidney Int. 2025;107(4):728-739. doi:10.1016/j.kint.2024.12.018
  220. Del Toro-Cisneros N, Zuñiga-González EY, Caballero-Islas AE, et al. Are medium cut-off membranes the future, or the promising reality for chronic haemodialysis patients? Rev Invest Clin. 2023;75(6):289-299. doi:10.24875/RIC.23000213
  221. Ronco C, Marchionna N, Brendolan A, et al. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018;33(Suppl 3):iii41–iii47. doi:10.1093/ndt/gfy202
  222. Lorenzin A, Neri M, Lupi A, et al. Quantification of internal filtration in hollow fiber hemodialyzers with medium cut-off membrane. Blood Purif. 2018;46(3):196–204. doi:10.1159/000489993.
  223. García-Prieto A, de la Flor JC, Coll E, et al. Expanded haemodialysis: what’s up, Doc? Clin Kidney J. 2023; 16:1071-1080. doi:10.1093/ckj/sfad033
  224. Kim TH, Kim SH, Kim TY, et al. Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study. BMC Nephrol. 2020; 21:2. doi:10.1186/s12882-019-1669-3
  225. Molano-Triviño A, Vesga J, Zuñiga E, et al. Efficiency of expanded haemodialysis at different dialysate flows. Nephrol Dial Transplant. 2021;36(1). https://doi.org/10.1093/ndt/gfab128.001
  226. Bland LA. Microbiological and endotoxin assays of haemodialysis fluids. Adv Ren Replace Ther. 1995;2(1):70-79. doi:10.1016/s1073-4449(12)80073-2.
  227. Skarupskiene I, Bumblyte IA, Tamošaitis D, et al. The level of endotoxins in haemodialysis water and dialysate in Lithuanian haemodialysis centers. Medicina (Kaunas). 2010;46(8):556-560. https://pubmed.ncbi.nlm.nih.gov/20966633/
  228. Ronco C. The Rise of Expanded Haemodialysis. Blood Purif. 2017;44(2):I-VIII. doi:10.1159/000476012
  229. Krishnasamy R, Hawley CM, Jardine MJ, et al. Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-off value membrane clearance of Albumin and Light chains in Haemodialysis patients. BMC Nephrology. 2018;19:89. https://doi.org/10.1186/s12882-018-0883-8
  230. Belmouaz M, Bauwens M, Hauet T, et al. Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transplant. 2020; 35:328–335. doi:10.1093/ndt/gfz189
  231. Sevinc M, Hasbal NB, Yilmaz V, et al. Comparison of circulating levels of uremic toxins in haemodialysis patients treated with medium cut-off membranes and high-flux membranes: Theranova in sisli hamidiye etfal (THE SHE) randomized control study. Blood Purif. 2020; 49(6):733–742. doi:10.1159/000508061
  232. Weiner DE, Falzon L, Skoufos L, et al. Efficacy and Safety of Expanded Haemodialysis with the Theranova 400 Dialyzer. A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2020; 15:1310–1319. https://doi.org/10.2215/CJN.01210120
  233. Zhao Y, Gan L, Niu Q, et al. Efficacy and safety of expanded haemodialysis in haemodialysis patients: a meta-analysis and systematic review. Ren Fail. 2022;44(1):541–550. doi:10.1080/0886022X.2022.2048855
  234. Yang J, Ke G, Liao Y, et al. Efficacy of medium cut-off dialyzers and comparison with high-flux dialyzers in patients on maintenance haemodialysis: A systematic review and meta-analysis. Ther Apher Dial. 2022; 26(4):756-768. doi:10.1111/1744-9987.13755
  235. Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016; 9:229–255. http://dx.doi.org/10.2147/IJGM.S102819
  236. Lowrie EG, Lew NL. Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15(5):458–482. doi:10.1016/s0272-6386(12)70364-520
  237. Fournier A, Birmelé B, François M, et al. Factors associated with albumin loss in post-dilution haemodiafiltration and nutritional consequences. Int J Artif Organs 2015;38(2):76-82. doi:10.5301/ijao.5000389.
  238. Maduell F. Haemodiafiltration versus conventional haemodialysis: should "conventional" be redefined? Semin Dial. 2018;31(6):625–632. ttps://doi.org/10.1111/sdi.12715
  239. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during haemodialysis. Kidney Int. 46: 830–837, 1994. doi:10.1038/ki.1994.339.
  240. Sombolos K, Tsitamidou Z, Kyriazis G, et al. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo. Am J Nephrol. 17: 406–412, 1997. doi:10.1159/000169131
  241. Caravaca F, Arrobas M, Dominguez C. Serum albumin and other serum protein fractions in stable patients on peritoneal dialysis. Perit Dial Int. 2000;20: 703–707. doi:10.1177/089686080002000621
  242. Rippe B, Öberg CM. Albumin Turnover in Peritoneal and Haemodialysis. Semin Dial. 2016; 29(6):458-462. doi:10.1111/sdi.12534.
  243. Macías N, Vega A, Abad S, et al. Is High-Volume Online Haemodiafiltration Associated with Malnutrition? Therapeutic Apheresis Dialysis. 2017; 21(4):361–369. doi:10.1111/1744 9987.12602
  244. Maduell F, Rodas L, Broseta JJ, et al. Medium Cut-Off Dialyzer Versus Eight Haemodiafiltration Dialyzers: Comparison Using a Global Removal Score. Blood Purif. 2019; 48 (2):167–174. https://doi.org/10.1159/000499759
  245. Maduell F, Broseta JJ, Rodríguez-Espinosa D, et al. Comparison of four medium cut-off dialyzers. Clin Kidney J. 2022;15(12):2292–2299. doi:10.1093/ckj/sfac167.
  246. Krieter DH, Rüth M, Lemke H-D, Wanner C. Clinical performance comparison of two medium cut-off dialyzers. Ther Apher Dial. 2022;27(2):284-292. doi:10.1111/1744-9987.13919.
  247. Hagemann F, Linkhorst J, Roth H, Wessling M. On the balance between albumin loss and removal of middle molecules in dialyzers. J Membrane Science Letters. 2023; 3:100044. https://doi.org/10.1016/j.memlet.2023.100044
  248. Bunch A, Sanchez R, Nilsson LG, et al. Medium Cut-Off Dialyzers in a Large Population of Haemodialysis Patients in Colombia: COREXH Registry,” Therapeutic Apheresis Dialysis. 2020; 25(1):33–43. https://doi.org/10.1111/1744-9987.13506
  249. Molano-Trivino AP, Hutchison CA, Sanchez R, et al. Medium Cutoff Versus High-Flux Haemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment Weighting. Kidney Med. 2022;7;4(4):100431. https://doi.org/10.1016/j.xkme.2022.100431
  250. Castillo JC, Vesga J, Rivera A, et al. On behalf of the Colombian Registry of Expanded Haemodialysis Investigators. “Variations in Serum Albumin Levels Over Time in Patients Treated with Conventional Haemodialysis or Expanded Haemodialysis: A Cohort Study,” Haemodialysis Int. 2025;29(3):327-334. https://doi.org/10.1111/hdi.13232.
  251. Cuvelier C, Tintillier M, Migali G, et al. Albumin losses during haemodiafiltration: all dialyzers are not created equal - a case report. Cuvelier et al. BMC Nephrology. 2019; 20:392. https://doi.org/10.1186/s12882-019-1567-8
  252. Ward RA, Beck W, Bernardo AA, et al. Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins? Nephrol Dial Transplant. 2019;34: 901–907. doi:10.1093/ndt/gfy236
  253. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. J Am Soc Nephrol. 2019;30(5):751-766. doi:10.1681/ASN.2018060609
  254. Lin CJ, Wu V, Wu PC, Chih-Jen Wu CJ. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS One. 2015;10(7):e0132589. doi:10.1371/journal.pone.0132589
  255. Wu PH, Lin YT, Chiu YW, et al. The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in haemodialysis patients. Sci Rep. 2021;11(1):3786. doi:10.1038/s41598-021-83383-x.
  256. Suhendra A, Ramadani S, Tarigan RR. Association Between Indoxyl Sulfate Levels and Major Cardiovascular Events in Haemodialysis Patients with Chronic Kidney Disease. J Soc Med. 2025;4(10):312-319. https://doi.org/10.71197/jsocmed.v4i10.259
  257. Nagai K, Tsuchida K, Ishihara N, et al. Implications of Albumin Leakage for Survival in Maintenance Haemodialysis Patients: A 7-year Observational Study. Ther Apher Dial. 2017; 21(4):378–386. doi:10.1111/1744-9987.12526
  258. Okada K, Tashiro M, Michiwaki H, et al. Effects of high albumin leakage on survival between online haemodiafiltration and super high-flux haemodialysis the HISTORY study. BMC Renal Replacement Therapy. 2022; 8:52. https://doi.org/10.1186/s41100-022-00440-5
  259. Lonnemann G. 119 The quality of dialysate: An integrated approach. Kidney Int. 2000;58, Suppl. 76: S112–S119. doi:10.1046/j.1523-1755.2000.07614.x
  260. Henrie M, Ford C, Andersen M, et al. In Vitro Assessment of Dialysis Membrane as an Endotoxin Transfer Barrier: Geometry, Morphology, and Permeability. Artificial Organs. 2008; 32(9):701-710. https://doi.org/10.1111/j.1525-1594.2008.00592.x
  261. Glorieux G, Schepers E, Schindler R, et al. A novel bioassay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant. 2009;24 (2): 548–554. doi:10.1093/ndt/gfn485
  262. Hulko M, Dietrich V, Koch I, et al. Pyrogen retention: Comparison of the novel medium cut-off (MCO) membrane with other dialyser membranes. Sci Rep. 2019;1;9(1):6791. doi:10.1038/s41598-019-43161-2
  263. Hulko M, Beck W, Koch I, et al. doi:10.5772/intechopen.109358. In "Updates on Haemodialysis " Book. Editor: Ayman Karkar. INTECH (2023) 978-1-80356-501-9. http://www.intechopen.com/books/updates-on-haemodialysis
  264. Schepers E, Glorieux, Eloot S, et al. Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up. BMC Nephrol. 2018; 5;19(1):1. doi:10.1186/s12882-017-0808-y.
  265. Stuard S, Mysayphonh C, Blankestijn PJ, et al. Drug Dosing in Post-Dilution Haemodiafiltration: Pharmacokinetic Principles and Clinical Implications. Clin Jam Soc Nephrol. 2026;1–19. https://doi.org/10.2215/CJN.0000001180
  266. Voigt M, Gebert M, Haug U, et al. Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration. Scientific Reports. 2019; 9:6370. doi.org/10.1038/s41598-019-42783-w
  267. Lucca IP, Armani R, Carvalh AB, et al. The effects of medium cut-off and high-flux membranes on activated clotting time of patients on haemodialysis. Front Nephrol. 2023 (23). https://doi.org/10.3389/fneph.2023.1133910
  268. Santos A, Macías N, Vega A, et al. Expanded haemodialysis: Is anticoagulation of the dialysis circuit different from online haemodiafiltration and high-flux haemodialysis ? Ther Apher Dial. 2022 Feb;26(1):147-153. doi:10.1111/1744-9987.13652
  269. Chen YY, Sun X, Huang W, He FF, Zhang C. Therapeutic apheresis in kidney diseases: an updated review. Ren Fail. 2022;19;44(1):842–857. doi:10.1080/0886022X.2022.2073892
  270. Allawati H, Dallas L, Nair S, et al. A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear). Toxins. 2020;12(5):317. doi:10.3390/toxins12050317
  271. Yeter HH, Korucu B, Akcay OF, et al. Effects of medium cut ‑off dialysis membranes on inflammation and oxidative stress in patients on maintenance haemodialysis. Int Urol Nephrol. 2020. https://doi.org/10.1007/s11255-020-02562-3
  272. Aylı BI, Okyay GU, Ayl ı MD. Impact of Expanded Haemodialysis on Inflammation and Iron Metabolism in Chronic Haemodialysis Patients. Semin Dial. 2026; 39:105–115. https://doi.org/10.1111/sdi.70033
  273. Zickler D, Schindler R, Willy K, et al. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients —A Randomized Controlled Clinical Trial. PLoS ONE. 2017;12(1): e0169024. https://doi.org/10.1371/journal.pone.0169024
  274. Catar R, Moll G, Kamhieh-Milz J, et al. Expanded Haemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling. Front Immunol. 2021; 12:774052. doi:10.3389/fimmu.2021.774052
  275. Comoglu M, Dede F, Yenigun EC, et al. Effects of Medium Cutoff Membranes on Pro-Inflammatory Cytokine and Oxidative Marker Levels in Patients with Sepsis Who Developed Acute Kidney Injury. Blood Purif. 2022;51(9):772-779. doi:10.1159/000519881
  276. Cozzolino M, Magagnoli L, Ciceri P, et al. Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2019;14(1):382-389. doi:10.1093/ckj/sfz155
  277. Willy K, Girndt M, Voelkl J, et al. Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro. Blood Purif. 2018;45 (1-3): 131–138. https://doi.org/10.1159/000484925
  278. Ciceri P, Tettamanti G, Galassi A, et al. Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study. Clin Kidney J. 2021;14(7):1798-1807. https://doi.org/10.1093/ckj/sfaa216
  279. Lim JH, Seo YJ, Jeon Y, et al. Expanded Haemodialysis with Theranova Dialyzer and Residual Kidney Function in Patients Starting Long-Term Haemodialysis: A Randomized Controlled Trial. J Am Soc Nephrol. 2025;36(8):1614–1625. https://doi.org/10.1681/ASN.0000000655
  280. Zhang JC, El-Majzoub S, Lic M, et al. Could symptom burden predict subsequent healthcare use in patients with end stage kidney disease on haemodialysis care? A prospective, preliminary study. Ren Fail. 2020;42(1):294-301. https://doi.org/10.1080/0886022X.2020.1744449
  281. Sukul N, Zhao J, Pisoni RL, et al. Pruritus in Haemodialysis Patients: Longitudinal Associations With Clinical and Patient-Reported Outcomes. Am J Kidney Dis. 2023;82(6):666-676. doi:10.1053/j.ajkd.2023.04.008
  282. Capelli I, Pizza F, Ruggeri M, et al. Time evolution of restless legs syndrome in haemodialysis patients. Clin Kidney J. 2021;14(1):341–347. doi:10.1093/ckj/sfz148
  283. Fukuma S, Shimizu S, Shintani A, et al. Development and validation of a prediction model for loss of physical function in elderly haemodialysis patients. Nephrol Dial Transplant. 2018;33(8):1452-1458. https://doi.org/10.1093/ndt/gfx260
  284. Bossola M, Di Stasio E, Monteburini T, et al. Recovery Time after Haemodialysis Is Inversely Associated with the Ultrafiltration Rate. Blood Purif. 2019;47(1-3):45-51. doi:10.1159/000492919
  285. Yonata A, Islamy N, Taruna A, Pura L. Factors Affecting Quality of Life in Haemodialysis Patients. Int J General Med. 2022; 15:7173–7178. doi:10.2147/IJGM.S375994
  286. Kandi M, Brignardello-Petersen R, Couban R, Wu C, Nesrallah G. Clinical Outcomes with Medium Cut-Off Versus High-Flux Haemodialysis Membranes: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis. 2022:9;1-16. doi:10.1177/20543581211067087
  287. Bolton S, Gair R, Nilsson LG, et al. Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Haemodialysis Therapy Mode. Patient Relat Outcome Meas. 2021;4(12):315-321. doi:10.2147/PROM.S325016
  288. Alarcon JC, Bunch A, Ardila F, et al. Colombian Registry of Expanded Haemodialysis Investigators. Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry. Blood Purif. 2021;50(1):110-118. doi:10.1159/000508803
  289. Penny JD, Jarosz P, Salerno FR, et al. Impact of Expanded Haemodialysis Using Medium Cut-off Dialyzer on Quality of Life: Application of Dynamic Patient-Reported Outcome Measurement Tool. Kidney Med. 2021;29;3(6):992-1002. doi:10.1016/j.xkme.2021.05.010
  290. Penny JD, Salerno FR, Akbari A, McIntyre CW. Pruritus: Is there a grain of salty truth? Haemodialysis Int. 2021;25(1): E10-E14. doi:10.1111/hdi.12885
  291. Lim JH, Park Y, Yook JM, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance haemodialysis patients. Sci Rep. 2020;8;10(1):7780. doi:10.1038/s41598-020-64622-z
  292. Blackowicz MJ, Falzon L, Beck W, et al. Economic evaluation of expanded haemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. Haemodialysis Int. 2022;26:449–455. doi: 10.1111/hdi.13015
  293. Sanabria RM, Hutchison CA, Vesga JI, et al. Expanded Haemodialysis and Its Effects on Hospitalizations and Medication Usage: A Cohort Study. Nephron. 2021;145(2):179–187. doi:10.1159/000513328
  294. Lim JH, Jeon Y, Yook JM, et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance haemodialysis patients: results from a randomized controlled trial. Sci Rep. 2020;10,16062. https://doi.org/10.1038/s41598-020-73124-x
  295. Castillo JC, Vesga J, Rivera A, et al. Survival Differences in Patients with High-Flux Haemodialysis versus Expanded Haemodialysis: A Cohort Study. Blood Purif. 2025;54(12):772-781. doi:10.1159/000548158
  296. de Sequera P, Pérez-García R, Vega A, et al. On behalf of the MOTheR collaborative network. Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online haemodiafiltration. Clin Kidney J. 2023; 16(11):2254–2261. https://doi.org/10.1093/ckj/sfad128
  297. de Sequera Ortiz P, Pérez García R, Martínez-Vaquera S, et al. MOTheR HDx Study: A MOPR Study to Explore Morbidity and Mortality in Patients Dialyzed with Theranova HDx Compared with OL-HDF. Abstract #27, ERA 2026.
  298. Pecoits-Filho R, Bieber B, Wang D, et al. The CONCORDIA Study: All-Cause Mortality with HDx with Theranova Compared with Haemodiafiltration Using DOPPS as an External Real-World Comparator. Abstract #167, ERA 2026.
  299. Mohamed O, Shaheen F, Safwat M, et al. The Budgetary Impact of Introducing HDx therapy enabled by Theranova Dialyzer compared to High-Flux Haemodialysis in private sector in the Kingdom of Saudi Arabia. ISPOR 2024, Poster No. EE 727
  300. Henderson S, Goux N, Mahsoub M, et al. Comparison of utility consumption between different modalities of in-center haemodialysis. ERA 2025; Poster No.TH-PO291.
  301. Fasseeh AN, Abaza N, Rostom I, et al. HDx versus HDF in End-Stage Kidney Disease: Cost-Minimization Study in Saudi Arabia. 2025-RS-6293-ISPORActivity
  302. Rivera A, Vesga J, Sanabria M, et al. A resource consumption analysis of expanded haemodialysis compared to online haemodiafiltration: A provider perspective in Spain. Nefrologia. 2026; NEFRO-501535. https://doi.org/10.1016/j.nefro.2026.501535.

Article information

Authors

How to cite

Karkar, A., 2026. Haemodialysis: From Basics to Bedside. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0680

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
78

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.